10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _________

Commission File No. 000-19333

Bion Environmental Technologies, Inc.

(Name of registrant in its charter)

Colorado	84-1176672
(State or other jurisdiction of incorporation or formation)	(I.R.S. employer identification number)

Box 566 / 1774 Summitview Way

Crestone, Colorado  81131

(Address of principal executive offices)

(212) 758-6622

(Registrant’s telephone number, including area code) 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Securities Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BNET	OTCQB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒  Yes   ☐  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).       ☒  Yes  ☐  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ☐	Accelerated filer  ☐
Non-accelerated filer    ☐	Smaller reporting company  ☒
Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   ☐  Yes   ☒  No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS: Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.   Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.  On May 1, 2019, there were 27,893,429 Common Shares issued and 27,189,120 Common Shares outstanding.

BION ENVIRONMENTAL TECHNOLOGIES, INC.

FORM 10-Q

TABLE OF CONTENTS

PART I.  FINANCIAL INFORMATION		Page
Item 1.	Financial Statements	3
	Consolidated financial statements (unaudited):
	Balance sheets	3
	Statements of operations	4
	Statement of changes in equity (deficit)	5
	Statements of cash flows	6
	Notes to unaudited consolidated financial statements	7-21
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	36
Item 4.	Controls and Procedures	36
PART II.  OTHER INFORMATION
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	37
Item 4.	Mine Safety Disclosures	37
Item 5.	Other Information	37
Item 6.	Exhibits	37
	Signatures	38

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe" or "continue" or the negative thereof or variations thereon or similar terminology.  The expectations reflected in forward-looking statements may prove to be incorrect.

2

PART I – FINANCIAL INFORMATION

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31,			June 30,
	2019			2018
	(unaudited)
ASSETS
Current assets:
Cash	$	149,169		$	22,013
Prepaid expenses		4,164			7,474
Deposits and other receivables		1,000			1,000
Total current assets		154,333			30,487
Property and equipment, net (Note 3)		2,964			1,448
Total assets	$	157,297		$	31,935
LIABILITIES AND EQUITY (DEFICIT)
Current liabilities:
Accounts payable and accrued expenses	$	672,507		$	719,633
Series B Redeemable Convertible Preferred stock, $0.01 par value,
50,000 shares authorized; 200 shares issued and outstanding,
liquidation preference of $35,500 and $34,000, respectively (Note 7)		32,900			31,400
Deferred compensation (Note 4)		844,122			421,641
Loan payable and accrued interest (Note 5)		9,228,213			9,028,983
Total current liabilities		10,777,742			10,201,657
Convertible notes payable - affiliates (Note 6)		3,619,099			3,525,216
Total liabilities		14,396,841			13,726,873
Deficit:
Bion's stockholders' equity (deficit):
Series A Preferred stock, $0.01 par value, 50,000 shares authorized,
no shares issued and outstanding		-			-
Series C Convertible Preferred stock, $0.01 par value,
60,000 shares authorized; no shares issued and outstanding		-			-
Common stock, no par value, 100,000,000 shares authorized, 27,795,695
and 25,939,892 shares issued, respectively; 27,091,386
and 25,235,583 shares outstanding, respectively		-			-
Additional paid-in capital		109,853,840			108,117,330
Subscription receivable - affiliates (Note 7)		(504,650	)		(174,650	)
Accumulated deficit		(123,638,875	)		(121,691,956	)
Total Bion’s stockholders’ deficit		(14,289,685	)		(13,749,276	)
Noncontrolling interest		50,141			54,338
Total deficit		(14,239,544	)		(13,694,938	)
Total liabilities and deficit	$	157,297		$	31,935

See notes to consolidated financial statements

3

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

THREE AND NINE MONTHS ENDED MARCH 31, 2019 AND 2018

(UNAUDITED)

	Three months ended						Nine months ended
	March 31,						March 31,
	2019			2018			2019			2018
Revenue	$	-		$	-		$	-		$	-
Operating expenses:
General and administrative (including stock-based
compensation  (Note 7))		305,137			956,826			1,272,626			2,077,519
Depreciation		271			436			966			1,308
Research and development (including stock-based
compensation (Note 7))		103,529			680,436			387,442			1,125,937
Total operating expenses		408,937			1,637,698			1,661,034			3,204,764
Loss from operations		(408,937	)		(1,637,698	)		(1,661,034	)		(3,204,764	)
Other expense (income):
Gain on extinguishment of liabilities		-			-			-			(718,580	)
Conversion inducement		-			8,000			-			8,000
Interest expense		100,282			84,714			290,082			276,815
Total other expense (income)		100,282			92,714			290,082			(433,765	)
Net loss		(509,219	)		(1,730,412	)		(1,951,116	)		(2,770,999	)
Net loss attributable to the noncontrolling interest		505			1,472			4,197			2,486
Net loss applicable to Bion's common stockholders	$	(508,714	)	$	(1,728,940	)	$	(1,946,919	)	$	(2,768,513	)
Net loss applicable to Bion's common stockholders
per basic and diluted common share	$	(0.01	)	$	(0.07	)	$	(0.07	)	$	(0.11	)
Weighted-average number of common shares outstanding:
Basic and diluted		26,842,776			24,465,814			26,291,097			24,253,807

See notes to consolidated financial statements

4

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

NINE MONTHS ENDED MARCH 31, 2019

(UNAUDITED)

	Bion's Shareholders'
	Series A Preferred Stock				Series C Preferred Stock				Common Stock				Additional paid-in			Subscription Rec-eivables			Accumulated			Noncontrolling			Total equity/
	Shares		Amount		Shares		Amount		Shares		Amount		capital			for Shares			deficit			interest			(deficit)
Balances, July 1, 2018		-		-		-		-		25,939,892		-		108,117,330			(174,650	)		(121,691,956	)		54,338			(13,694,938	)
Issuance of common stock for services		-		-		-		-		70,042		-		45,256			-			-			-			45,256
Vesting of options for services		-		-		-		-		-		-		123,250			-			-			-			123,250
Modification of options		-		-		-		-		-		-		222,300			-			-			-			222,300
Sale of units		-		-		-		-		1,584,733		-		792,365			-			-			-			792,365
Commissions on sale of units		-		-		-		-		1,028		-		(53,437	)		-			-			-			(53,437	)
Modification of warrants		-		-		-		-		-		-		170,526			-			-			-			170,526
Issuance of warrants		-		-		-		-		-		-		336,250			(330,000	)		-			-			6,250
Conversion of debt and liabilities		-		-		-		-		200,000		-		100,000			-			-			-			100,000
Net loss		-		-		-		-		-		-		-			-			(1,946,919	)		(4,197	)		(1,951,116	)
Balances, March 31, 2019		-	$	-		-	$	-		27,795,695	$	-	$	109,853,840		$	(504,650	)	$	(123,638,875	)	$	50,141		$	(14,239,544	)

See notes to consolidated financial statements

5

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

NINE MONTHS ENDED MARCH 31, 2019 AND 2018

(UNAUDITED)

	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(1,951,116	)	$	(2,770,999	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		966			1,308
Accrued interest on loan payable, deferred compensation and other		308,957			303,189
Stock-based compensation		567,582			2,101,160
Gain on extinguishment of liabilities		-			(718,580	)
Conversion inducement		-			8,000
Decrease in prepaid expenses		3,310			2,321
(Decrease) increase in accounts payable and accrued expenses		(34,189	)		80,749
Increase in deferred compensation		495,200			610,200
Net cash used in operating activities		(609,290	)		(382,652	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(2,482	)		-
Net cash used in investing activities		(2,482	)		-
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of units		792,365			306,997
Commissions on sale of units		(53,437	)		(14,875	)
Proceeds from exercise of warrants		-			40,001
Repayment of loans payable - affiliates		-			(12,500	)
Proceeds from loans payable - affiliates		-			30,500
Net cash provided by financing activities		738,928			350,123
Net increase (decrease) in cash		127,156			(32,529	)
Cash at beginning of period		22,013			72,932
Cash at end of period		149,169		$	40,403
Supplemental disclosure of cash flow information:
Cash paid for interest	$	-		$	-
Non-cash investing and financing transactions:
Purchase of warrants for subscription receivable - affiliates	$	330,000		$	134,650
Conversion of debt and liabilities	$	100,000		$	-
Shares issued for warrant exercise commissions	$	514		$	-
Warrants issued for unit commissions	$	4,850		$	-
Forgiveness of deferred compensation - related parties	$	-		$	1,685,252

See notes to consolidated financial statements

6

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED MARCH 31, 2019 AND 2018

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

Organization and nature of business:

Bion Environmental Technologies, Inc. (“Bion” or “We” or the “Company”) was incorporated in 1987 in the State of Colorado and has developed and continues to develop patented and proprietary technology and business models that provide comprehensive environmental solutions to a significant source of pollution in United States agriculture, large scale livestock facilities known as Concentrated Animal Feeding Operations (“CAFO’s”). Application of our technology and technology platform can simultaneously remediate environmental problems and improve operational/resource efficiencies by recovering value from the CAFOs’ waste stream that has traditionally been wasted or underutilized, including renewable energy, nutrients (nitrogen and phosphorus)--- in organic and conventional form-- and clean water. Bion’s technologies (and applications related thereto) produce substantial reductions of nutrient releases (primarily nitrogen and phosphorus) to both water and air (including ammonia, which is subsequently re-deposited to the ground) from livestock waste streams based upon our operations and research to date (and third party peer review thereof). Our technology simultaneously enables the documentation of the remediation efforts thereby providing the basis for product branding which addresses consumer concerns regarding sustainability and food safety.  We are continually involved in research and development to upgrade and improve our technology and technology applications, including integration with third party technology. Bion provides comprehensive and cost-effective treatment of livestock waste onsite (and/or at nearby locations), while it is still concentrated and before it contaminates air, soil, groundwater aquifers and/or downstream waters, and, in certain configurations, can be optimized to maximize recovery of marketable nutrients for potential use as fertilizer (organic and/or inorganic) and/or feed additives plus renewable energy (and related environmental credits).

From 2014 through the current 2019 fiscal year, the Company has focused its research and development on augmenting the basic ‘separate and aggregate’ approach of its technology platform to provide additional flexibility and to increase recovery of marketable nutrient by-products (in organic and non-organic forms) and renewable energy production (either/both biogas and/or renewable electricity), thereby increasing potential related revenue streams and reducing dependence of its future projects on the monetization of nutrient reductions (which still remain an important part of project revenue streams).  Bion has worked on development of its third generation technology (“3G Tech”) which is designed to: a) generate significantly greater value from the nutrients and renewable energy recovered from the waste stream, b) treat dry (poultry) waste streams as well as wet waste streams (dairy/beef cattle/swine) while c) maintaining or improving environmental performance. This research and development effort also involves ongoing review of potential “add-ons” and applications to our technology platform for use in different regulatory and/or climate environments. These research and development activities have targeted completion of development of the next generation of Bion’s technology and technology platform. We believe such activities will continue at least through the 2019 calendar year (and likely longer), subject to availability of adequate financing for the Company’s operations, of which there is no assurance.  Such activities may include design and construction of an initial, commercial-scale module utilizing our 3G Tech to assist in optimization efforts before construction of the full Kreider 2 project (see below) and other Projects.

For the past decade, Bion has been directed toward creating applications of our patented and proprietary waste management technologies and technology platform to pursue JVs in three main business opportunities:

1) Installation of Bion systems to retrofit and environmentally remediate existing large CAFOs (“Retrofits” and “Retrofit Projects”) in selected markets where:

a) government policy supports such efforts (such as the Chesapeake Bay watershed, Great Lakes Basin states, and/or other states and watersheds facing EPA ‘total maximum daily load’ (“TMDL”) issues), and/or

b) CAFO’s need our technology to obtain permits to expand or develop without negative environmental consequences.

2)   Development of new state-of-the-art large scale waste treatment facilities (now utilizing the Company’s 3G Tech) which may be developed in conjunction with new CAFOs in strategic locations that were previously impracticable due to environmental impacts or to treat the waste streams from one or more existing large livestock facilities (“Projects”).  Some of these Projects may be either a) Integrated Projects as described below,  b) ‘central processing facilities’ which receive the waste from multiple livestock facilities, c) Retrofit Projects or  d) hybrids with elements of each of these types.  Each version will be able to realize revenue from multiple revenue streams potentially generated by our 3G Tech.

7

3) Licensing and/or joint venturing of Bion’s technology and applications (primarily) outside North America.

In both categories 1) and 2) above, the Company intends to directly participate (whether by joint venture agreement or other contractual arrangements) in the revenues of the Retrofits and Projects.

The opportunities described at 1) and 2) above each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion’s efforts are focused on such political and regulatory matters. Bion currently intends to pursue the international opportunities primarily through the use of consultants with existing relationships in target countries.

At this time, our primary focus is on category 2)  above using our 3G Tech to develop new (or expanded) large-scale Projects with strategic partners (including the Kreider 2 Project) on a joint venture (or other participating contractual form)  basis.  Bion’s business model opens up the opportunity for JV’s in various forms based upon the revenue generated by our 3G Tech platform from nutrient reductions, fertilizer co-products and renewable natural gas (which revenue streams will be secured through long term take-off agreements for each of these co-products) providing initial support for financing of required capital expenditures (whether equity or debt).  We anticipate that these revenue streams will be supplemented by revenue realized from long-term premium pricing resulting from the sustainable branding opportunity. We believe that the branding opportunity may provide the single largest contribution to the economic opportunity over time.

During 2008 the Company commenced actively pursuing the opportunity presented by environmental retrofit and remediation of the waste streams of existing CAFOs which effort has met with very limited success to date. The first commercial activity in this area is represented by our agreement with Kreider Farms (“KF”), pursuant to which the Kreider 1 system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered  full-scale operation during 2011. On January 26, 2009 the Board of the Pennsylvania Infrastructure Investment Authority (“Pennvest”) approved a $7.75 million loan to Bion PA 1, LLC (“PA1”), a wholly-owned subsidiary of the Company, for the initial Kreider Farms project (“Kreider 1 System”). After substantial unanticipated delays, on August 12, 2010 PA1 received a permit for construction of the Kreider 1 System.  Construction activities commenced during November 2010.  The closing/settlement of the Pennvest Loan took place on November 3, 2010.  PA1 finished the construction of the Kreider 1 System and entered a period of system ‘operational shakedown’ during May 2011.  The Kreider 1 System reached full, stabilized operation by the end of the 2012 fiscal year.  During 2011 the Pennsylvania Department of Environmental Protection (“PADEP”) re-certified the nutrient credits for this project.  The PADEP issued final permits for the Kreider 1 System (including the credit verification plan) on August 1, 2012 on which date the Company deemed that the Kreider 1 System was ‘placed in service’.  As a result, PA1 commenced generating nutrient reduction credits for potential sale while continuing to utilize the Kreider 1 System to test improvements and add-ons. However, to date liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth,  which limited liquidity/depth has negatively impacted Bion’s business plans and has resulted in challenges to monetizing the nutrient reductions created by PA1’s existing Kreider 1 System and Bion’s other proposed projects. These difficulties have prevented PA1 from generating any material revenues from the Kreider 1 System to date and raise significant questions as to when, if ever, PA1 will be able to generate such revenues fromthe Kreider 1 System.  PA1 has had sporadic discussions/negotiations with Pennvest related to forbearance and/or re-structuring its obligations pursuant to the Pennvest Loan for more than four years. In the context of such discussions/negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013.  Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of March 31, 2019.  Due to the failure of the Pennsylvania nutrient reduction credit market to develop, the Company determined (on three separate occasions) that the carrying amount of the property and equipment related to the Kreider 1 System exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits.  Therefore, PA1 and the Company recorded impairments related to the value of the Kreider 1 assets totaling $3,750,000 through June 30, 2015.  During the 2016 fiscal year, PA1 and the Company recorded an additional impairment of $1,684,562 to the value of the Kreider 1 assets which reduced the value on the Company’s books to zero.  This impairment reflects management’s judgment that the salvage value of the Kreider 1 assets roughly equals PA1’s contractual obligations related to the Kreider 1 System, including expenses related to decommissioning of the Kreider 1 System, costs associated with needed capital upgrade expenses, and re-certification/ permitting amendments.

8

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and does not have the resources to make the payments demanded by Pennvest. PA1 has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected PA1’s proposal made during the fall of 2014.  No formal proposals are presently under consideration and only sporadic communication has taken place regarding the matters involved over the last 48 months.  It is not possible at this date to predict the outcome of such this matter, but the Company believes that a loan modification agreement (coupled with an agreement regarding an update and re-start of full operations of the Kreider 1 System) may be reached in the future if/when a more robust market for nutrient reductions develops in Pennsylvania, of which there is no assurance. PA1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days.

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 System met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been (and is now) solely an obligation of PA1 since that date.

The economics (potential revenues, profitability and continued operation) of the Kreider 1 System are based almost entirely on the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up.

On May 5, 2016, Bion PA2 LLC (“PA2”) executed a stand-alone joint venture agreement with Kreider Farms covering matters related to development and operation of a system to treat the waste streams from Kreider’s poultry facilities (“Kreider 2”).

The Kreider projects are owned and operated by Bion through separate subsidiaries, in which Kreider has the option to acquire a noncontrolling interest. Substantial capital (equity and/or debt) has been and will continue to be expended on these projects. Additional funds will be required for continuing operations and additional capital expenditures for upgrades at Kreider 1 until sufficient revenues can be generated, of which there is no assurance. The Company anticipates that the Kreider 1 System will generate revenue primarily from the sale of nutrient reduction (and/or other) environmental credits. A portion of Bion’s research and development activities has taken place at the Kreider 1 facility.

Kreider Farms –  3G Tech Project

Bion is completing an envelope of policy change and technology pilots that will allow it to move forward with the first commercial large scale 3G Tech project at Kreider Farms. Having recently received a Notice of Allowance of the initial 3G Tech patent (and subsequent filing of related additional patent applications/continuations), Bion is focused on two key tasks during the remainder of the 2019 fiscal and calendar year that will ‘complete the envelope’ and allow Bion to launch active development of the Kreider 2 poultry project (and/or other Projects) in 2019:

1. Support for adoption of PA SB 575 (successor to SB 799):  This will create a competitively-bid market for nutrient reductions/Credits that we believe will provide support for project financing for Kreider 2 prior to development of markets for the coproducts from Kreider 2 are established.

2. Installation of a small-scale 3G Tech ammonia recovery system to produce ammonium bicarbonate to be used for grower trials and to make application to OMRI for organic certification.

The 3G Tech Kreider 2 Project is planned for two (or more) locations. It is intended to treat the waste from Kreider’s 1,800 dairy cows and approximately six million egg layer chickens (with capacity for an additional three million layers). The Kreider 2 Project will be designed with modules with capacity of 450 tons (or more) per day of waste and will remove nitrogen and phosphorus from the waste stream that will be converted into high-value coproducts instead of polluting local and downstream waters. The Kreider 2 Project is planned to be built in three phases and may be expanded to include a ‘central processing facility’ with modules that will accept transported waste from the region on fee basis.

Bion has a long-standing relationship with Kreider Farms including a 2016 joint venture agreement related to this facility. Kreider has already made a significant investment in upgrading its poultry facilities to maximize the treatment and recovery efficiencies that can be achieved with Bion’s technology. We are cautiously optimistic that once PA SB575 (the recently introduced successor to SB799) will be passed during the current fiscal year and that once passed, a market will be put in place for long-term commercial sale of the nutrient reduction credits produced at Kreider 2. Bion anticipates that it may require up to 6 months after SB575 becomes law to develop the rules/regulations related to the competitive bidding program. If the competitive bidding program is implemented, we intend to arrange project financing for the Kreider 2 Project during 2019.

9

Assuming there are positive developments related to the market for nutrient reductions in Pennsylvania, the Company intends to pursue development, design and construction of the Kreider 2 poultry waste/renewable energy project with a goal of achieving operational status for its initial modules during 2020. However, as discussed above, this Project faces challenges related to the current limits of the existing nutrient reduction market and funding of technology-based, verifiable agricultural nutrient reductions which are anticipated to constitute the largest share of its revenues.

Bion’s current long-term goal is to acquire or develop, or have in a development pipeline, 6 to 12 Projects over the next 36 to 48 months.

 A significant portion of Bion’s activities concern efforts with private and public stakeholders (at local and state level) in Pennsylvania (and other Chesapeake Bay and Midwest and Great Lakes states) and at the federal level EPA and the Department of Agriculture (“USDA”) (and other executive departments) and Congress) to establish appropriate public policies which will create regulations and funding mechanisms that foster installation of the low cost environmental solutions that Bion (and others) can provide through clean-up of agricultural waste streams. The Company anticipates that such efforts will continue in Pennsylvania and other Chesapeake Bay watershed states throughout the next 12 months and in various additional states thereafter.

Going concern and management’s plans:

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses (including significant non-cash expenses) of approximately $3,018,000 and $2,463,000 during the years ended June 30, 2018 and 2017, respectively, and a net loss of approximately $1,951,000 during the nine months ended March 31, 2019.  At March 31, 2019, the Company has a working capital deficit and a stockholders’ deficit of approximately $10,623,000 and $14,290,000, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

During the years ended June 30, 2018 and 2017, the Company received total proceeds of approximately $418,000 and $452,000 from the sale of its debt and equity securities. Proceeds during the 2018 and 2017 fiscal years have been lower than in earlier years which reduction has negatively impacted the Company’s business development efforts.

During the nine months ended March 31, 2019, the Company received gross proceeds of approximately $792,000 from the sale of its equity securities and paid approximately $53,000 in commissions.

During fiscal years 2018 and 2017, the Company continued to experience greater difficulty in raising equity funding than in the prior years. As a result, the Company faced, and continues to face, significant cash flow management challenges due to working capital constraints. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 4 and 6) and members of the Company’s senior management have made loans to the Company. During the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000.  Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company does not have greater success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), management will need to consider deeper cuts (including additional personnel cuts) and curtailment of operations (including possibly Kreider 1 operations) and/or research and development activities.

10

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including Integrated Projects and the Kreider 2 facility) and CAFO Retrofit waste remediation systems and to continue to operate the Kreider 1 facility. The Company anticipates that it will seek to raise from $2,500,000 to $50,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in recent periods and the extremely unsettled capital markets that presently exist (especially for companies like us), that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations and/or proposed Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

2.SIGNIFICANT ACCOUNTING POLICIES

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, PA1, and PA2; and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).  The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at March 31, 2019, and the results of operations and cash flows of the Company for the three and nine months ended March 31, 2019 and 2018.  Operating results for the three and nine months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending June 30, 2019.

Cash and cash equivalents:

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents.

Property and equipment:

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s balance sheet) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.  The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

Stock-based compensation:

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

11

Derivative Financial Instruments:

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

Warrants:

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

Concentrations of credit risk:

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash.  The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits.  The Company has not experienced any losses on such accounts.

Noncontrolling interests:

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations.  In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

Fair value measurements:

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

Level 3 – assets and liabilities whose significant value drivers are unobservable.

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the   deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

12

Revenue Recognition:

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Loss per share:

Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share.  During the three and nine months ended March 31, 2019 and 2018, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:

	March 31, 2019		March 31, 2018
Warrants		16,591,570		12,176,269
Options		7,106,600		6,827,225
Convertible debt		8,449,932		7,337,805
Convertible preferred stock		17,750		16,750

The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the three and nine months ended March 31, 2019 and 2018:

	Three months ended March 31, 2019			Three months ended March 31, 2018			Nine months ended March 31, 2019			Nine months ended March 31, 2018
Shares issued – beginning of period		27,121,371			25,011,939			25,939,892			24,748,213
Shares held by subsidiaries (Note 7)		(704,309	)		(704,309	)		(704,309	)		(704,309	)
Shares outstanding – beginning of period		26,417,062			24,307,630			25,235,583			24,043,904
Weighted average shares issued     during the  period		425,714			158,184			1,055,514			209,903
Diluted weighted average shares –     end of   period		26,842,776			24,465,814			26,291,097			24,253,807

Use of estimates:

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recent Accounting Pronouncements:

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

In May 2017, the FASB issued ASU No. 2017-09 “Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment awards must be accounted for as modifications.  The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications.  ASU No. 2017-09 will be applied prospectively to awards modified on or after the adoption date.  The guidance is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted.  The adoption of ASU 2017-09 did not have a material impact on the Company’s financial statements.

13

3.PROPERTY AND EQUIPMENT:

Property and equipment consists of the following:

	March 31, 2019			June 30, 2018
Machinery and equipment	$	2,222,670		$	2,222,670
Buildings and structures		401,470			401,470
Computers and office equipment		173,245			171,613
		2,797,385			2,795,753
Less accumulated depreciation		(2,794,421	)		(2,794,305	)
	$	2,964		$	1,448

Management reviewed property and equipment for impairment as of June 30, 2016 and determined that the carrying amount of property and equipment related to the Kreider 1 project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits and potentially needed capital expenditures and it was also determined that the salvage value of the system components will be offset by contractual decommissioning obligations. Kreider 1 was measured at estimated fair value on a non-recurring basis using level 3 inputs, which resulted in an impairment of $1,684,562 of the property and equipment for the year ended June 30, 2016. As of June 30, 2016, the net book value of Kreider 1 was zero. As of March 31, 2019, management believes that no additional impairment exists.

Depreciation expense was $271 and $436 for the three months ended March 31, 2019 and 2018, respectively and $966 and $1,308 for the nine months ended March 31, 2019 and 2018, respectively.

4.DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $844,122 and $345,929 as of March 31, 2019 and 2018, respectively. Included in the deferred compensation balances as of March 31, 2019, are $447,019 and $79,016 owed Dominic Bassani (“Bassani”), the Company’s Chief Executive Officer and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of March 31, 2018 was $124,612 and $72,355, respectively. The Company also owes various consultants, pursuant to various agreements, for deferred compensation of $244,603 and $75,478 as of March 31, 2019 and 2018, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 3% per annum. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until December 31, 2019 (to be issued pursuant to the 2006 Plan). Smith has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement.  The Company also owes a current employee deferred compensation of $984 which is convertible into 1,348 shares of the Company’s common stock as of March 31, 2019 and, a former employee $72,500, which is not convertible and is non-interest bearing.

During the nine months ended March 31, 2019, Smith elected to convert deferred compensation and accounts payable of $87,063 and $12,937, respectively, into an aggregate 200,000 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share until December 31, 2022.

The Company recorded interest expense of $14,344 ($11,048 with related parties) and $32,299 ($26,084 with related parties) for the nine months ended March 31, 2019 and 2018, respectively.

14

5.LOAN PAYABLE:

PA1, the Company’s wholly-owned subsidiary, owes $9,228,213 as of March 31, 2019 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $1,474,213 as of March 31, 2019. The terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrues interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $3,502,000 in fiscal years 2013 through 2018, and $771,000 in fiscal year 2019, $794,000 in fiscal year 2020, $819,000 in fiscal year 2021, $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 thereafter. The Pennvest Loan is collateralized by the Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest is entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined.  The Company has incurred interest expense related to the Pennvest Loan of $59,109 and $49,373 for the three months ended March 31, 2019 and 2018, respectively.  The Company has incurred interest expense related to the Pennvest Loan of $172,856 and $148,121 for the nine months ended March 31, 2019 and March 31, 2018, respectively.  Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market to date, PA1 commenced negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan. In the context of such negotiations, PA1 has elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of March 31, 2019.

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and does not have the resources to make the payment demanded by Pennvest. PA1 has engaged in on/off discussions and negotiations with Pennvest concerning this matter but no such discussions/negotiations are currently active. As of the date of this report, no formal proposals are presently under consideration and only sporadic communication has taken place regarding the matters involved over the past 48 months. It is not possible at this date to predict the outcome of this matter, but the Company believes it is possible that an agreement may yet be reached that will result in a viable loan modification. Subject to the results of the negotiations with Pennvest and pending development of a more robust market for nutrient reductions in Pennsylvania, PA1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days.

In connection with the Pennvest Loan financing documents, the Company provided a ‘technology guaranty’ regarding nutrient reduction performance of Kreider 1 which was structured to expire when Kreider 1’s nutrient reduction performance had been demonstrated. During August 2012 the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 System had surpassed the requisite performance criteria and that the Company’s ‘technology guaranty’ was met. As a result, the Pennvest Loan is solely an obligation of PA1.

6.CONVERTIBLE NOTES PAYABLE - AFFILIATES:

January 2015 Convertible Notes

The January 2015 Convertible Notes accrue interest at 4% per annum and were due and payable on December 31, 2017. Effective June 30, 2017, the maturity dates were extended on the January 2015 Convertible Notes until July 1, 2019 and were further extended to July 1, 2021 effective September 30, 2018.  The January 2015 Convertible Notes (including accrued interest, plus all future deferred compensation), are convertible, at the sole election of the noteholder, into Units consisting of one share of the Company’s common stock and one half warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until December 31, 2020. The warrant contained in the Unit shall be exercisable at $1.00 per share until December 31, 2020. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”.

15

As of March 31, 2019, the January 2015 Convertible Note balances, including accrued interest, owed Bassani, Smith and Edward Schafer (“Schafer”), the Company’s Vice Chairman, were $1,713,318, $889,703 and $442,547, respectively.  As of March 31, 2018, the January 2015 Convertible Note balances, including accrued interest, owed Bassani, Smith and Schafer were $1,654,736, $859,282 and $427,416, respectively.  The Company recorded interest expense related to the January 2015 Convertible Notes of $25,677 for both of the three months ended March 31, 2019 and 2018, respectively.  The Company recorded interest expense of $78,172 for both the nine months ended March 31, 2019 and 2018, respectively.

During the nine months ended March 31, 2019, the Company agreed to sell Bassani and Smith, 3,000,000 and 300,000 warrants, respectively, exercisable at $0.60 per share until June 30, 2025 and June 30, 2023, respectively. The purchase price for the warrants is $0.10 per warrant and is payable with secured promissory notes of $300,000 and $30,000 from Bassani and Smith, respectively, both of which are secured by portions of their January 2015 Convertible Notes (Note 7).  The promissory notes accrue interest at 4% per annum and as of March 31, 2019 the accrued interest owed by Bassani and Smith is $7,956 and $796, respectively.

September 2015 Convertible Notes

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The initial principal balances of the September 2015 Convertible Notes were $405,831, $16,382 and $82,921, respectively. The September 2015 Convertible Notes bear interest at 4% per annum, had maturity dates of December 31, 2017 and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists. During the year ended June 30, 2018, Bassani and the Company agreed to split his original September 2015 Convertible Note into two replacement notes with all the terms remaining the same.  One of the replacement notes’ original principal is $130,000, which is being held by the Company as collateral for a subscription receivable promissory note from Bassani.  During the nine months ended March 31, 2019, with the Company’s approval, Bassani sold $300,000 of his second replacement note to a Shareholder with all the terms remaining the same.

The balances of the September 2015 Convertible Notes as of March 31, 2019, including accrued interest owed Bassani, Schafer and Shareholder, are $158,544, $18,716 and $396,271, respectively. The balances of the September 2015 Convertible Notes as of March 31, 2018, including accrued interest, were $447,989, $18,061 and $91,417, respectively.

Effective June 30, 2017, the maturity dates of the September 2015 Convertible Notes due Bassani and Schafer were extended until July 1, 2019 and during the year ended June 30, 2018, the maturity date of the note due a Shareholder was extended until July 1, 2019.  During the nine months ended March 31, 2019, the maturity dates of the all the September 2015 Convertible Notes were extended until July 1, 2021.

The Company recorded interest expense of $5,293 and $5,341 for the three months ended March 31, 2019 and 2018, respectively.   The Company recorded interest expense of $15,712 and $15,743 for the nine months ended March 31, 2019 and 2018, respectively.

7.STOCKHOLDERS' EQUITY:

Series B Preferred stock:

At July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares have reached their maturity date, but due to the cash constraints of the Company have not been redeemed.

During the years ended June 30, 2018 and 2017, the Company declared dividends of $2,000 and $2,000 respectively.  During the nine months ended March 31, 2019, the Company declared dividends of $1,500.  At March 31, 2019, accrued dividends payable are $15,500.  The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements.

16

Common stock:

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

During the nine months ended March 31, 2019, the Company issued 70,042 shares of the Company’s common stock at prices ranging from $0.50 to $0.74 per share for services valued at $45,256, in the aggregate, to a consultant and an employee.

During the nine months ended March 31, 2019, the Company issued 1,028 shares as commissions for the warrant exercises during the year ended June 30, 2018 valued at $514.

During the nine months ended March 31, 2019, the Company entered into subscription agreements under three different offerings to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share with expiry dates ranging from June 30, 2019 through December 31, 2020, and pursuant thereto, the Company issued 1,584,733 units for total proceeds of $792,365, net proceeds of $738,928 after commissions.  The Company allocated the proceeds from the 1,584,733 shares and the 792,369 warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be $0.05 per warrant. As a result, $28,176 was allocated to the warrants and $764,189 was allocated to the shares, and both were recorded as additional paid in capital.

During the nine months ended March 31, 2019, Smith elected to convert deferred compensation and accounts payable of $87,063 and $12,937, respectively, into an aggregate 200,000 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share until December 31, 2022.

Warrants:

As of March 31, 2019, the Company had approximately 16.6 million warrants outstanding, with exercise prices from $0.60 to $2.00 and expiring on various dates through June 30, 2025.

The weighted-average exercise price for the outstanding warrants is $0.95, and the weighted-average remaining contractual life as of March 31, 2019 is 3.8 years.

During the nine months ended March 31, 2019, warrants to purchase 70,069 shares of common stock of the Company at prices ranging from $0.85 to $3.00 per share expired.

During the nine months ended March 31, 2019, the Company entered into subscription agreements under three different offerings to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share with expiry dates ranging from June 30, 2019 through December 31, 2020, and pursuant thereto, the Company issued 1,584,733 units for total proceeds of $792,365, net proceeds of $738,928 after commissions.  The Company allocated the proceeds from the 1,584,733 shares and the 792,369 warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be $0.05 per warrant. As a result, $28,176 was allocated to the warrants and $764,189 was allocated to the shares, and both were recorded as additional paid in capital.

During the nine months ended March 31, 2019, the Company received an interest bearing, secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2025.  The promissory note bears interest at 4% per annum, is secured by Bassani’s January 2015 Convertible Note and as of March 31, 2019 the accrued interest was $7,956.  The secured promissory note is payable July 1, 2020.

17

During the nine months ended March 31, 2019, the Company received an interest bearing, secured promissory note for $30,000 from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of December 31, 2023.  The warrants have a 75% exercise bonus.  The promissory note bears interest at 4% per annum, is secured by Smith’s 2015 January 2015 Convertible Note and as of March 31, 2019 the accrued interest was $796.  The secured promissory note is payable on July 1, 2020.

During the nine months ended March 31, 2019, Smith elected to convert deferred compensation and accounts payable of $87,063 and $12,937, respectively, into an aggregate 200,000 units at $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share until December 31, 2022.

During the nine months ended March 31, 2019, the Company issued 125,000 warrants to a consultant to purchase 125,000 shares of the Company’s restricted common stock, which warrants have exercise prices ranging between $0.74 and $1.20 per share and have expiry dates of ranging from August 27, 2020 through October 27, 2020.  The warrants were in exchange for services expensed at $6,250, in aggregate.

During the nine months ended March 31, 2019, the Company agreed to extend the expiration dates of 5,229,188 warrants owned by certain individuals (including 1,765,000 owned by Bassani and 3,104,010 owned by Smith) which were scheduled to expire at various dates ranging from September 30, 2018 through December 31, 2021.  The Company recorded non-cash compensation expense related to the modification of the warrants of $163,026 ($88,250 and $68,758 for Bassani and Smith, respectively) and $7,500 as interest expense.

Stock options:

The Company’s 2006 Consolidated Incentive Plan, as amended (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years.

During the nine months ended March 31, 2019, the Company approved the modification of existing stock options held by Smith, which extended certain expiration dates.  The modifications resulted in incremental non-cash compensation of $222,300.

The Company recorded compensation expense related to employee stock options of $5,250 and $1,269,700 for the three months ended March 31, 2019 and 2018, respectively, and $123,250 and $1,369,350 for the nine months ended March 31, 2019 and 2018, respectively. The Company granted 350,000 and 2,647,500 options during the nine months ended March 31, 2019 and 2018, respectively.

The fair value of the options granted during the nine months ended March 31, 2019 and 2018 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

	Weighted Average, March 31, 2019	Range, March 31, 2019	Weighted Average, March 31, 2018	Range, March 31, 2018
Volatility	69%	58%-76%	74%	68%-75%
Dividend yield	-	-	-	-
Risk-free interest rate	2.71%	2.52%-2.78%	2.44%	1.75%-2.64%
Expected term (years)	3.8	1.9 to 4.3	5	3-6

The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

18

A summary of option activity under the 2006 Plan for the nine months ended March 31, 2019 is as follows:

	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at July 1, 2018		6,827,225		$	1.11		3.8	$	-
Granted		350,000			0.68
Exercised		-			-
Forfeited		-			-
Expired		(70,625	)		1.26
Outstanding at March 31, 2019		7,106,600		$	1.09		3.3	$	57,050
Exercisable at March 31, 2019		7,106,600		$	1.09		3.3	$	57,050

The following table presents information relating to nonvested stock options as of March 31, 2019:

	Options			Weighted Average Grant-Date Fair Value
Nonvested at July 1, 2018		-		$	-
Granted		350,000			0.35
Vested		(350,000	)		0.35
Nonvested at March 31, 2019		-		$	-

The total fair value of stock options that vested during the nine months ended March, 2019 and 2018 was $123,250 and $1,376,250 respectively. As of March 31, 2019, the Company had no unrecognized compensation cost related to stock options.

Stock-based employee compensation charges in operating expenses in the Company’s financial statements for the three and nine months ended March 31, 2019 and 2018 are as follows:

	Three months ended March 31, 2019		Three months ended March 31, 2018		Nine months ended March 31, 2019		Nine months ended March 31, 2018
General and administrative:
Fair value of stock bonuses expensed	$	-	$	1,500	$	-	$	8,723
Change in fair value from modification of     option terms		-		-		211,185		243,761
Change in fair value from modification of     warrant terms		-		7,091		118,233		163,956
Fair value of stock options expensed		5,250		682,485		97,375		782,135
Total	$	5,250	$	691,076	$	426,793	$	1,198,575
Research and development:
Fair value of stock bonus expensed	$	-	$	-	$	-	$	15,098
Change in fair value from modification of     option terms		-		-		11,115		105,895
Change in fair value from modification of     warrant terms		-		219		44,793		132,896
Fair value of stock options expensed		-		587,215		25,875		587,215
Total	$	-	$	587,434	$	81,783	$	841,104

19

8.COMMITMENTS AND CONTINGENCIES:

Employment and consulting agreements:

Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements and terms since March 2003.  Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003.  On October 10, 2016, the Company approved a month to month contract extension with Smith which includes provisions for i)  a monthly deferred salary of $18,000 effective October 1, 2016 until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which  was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, and subsequently extended until December 31, 2019), and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties.  Smith agreed effective July 29, 2018 to continue to serve the Company under these terms.

Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani, through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011.  On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation.  During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, and subsequently extended until December 31, 2019).  During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO, while a detailed, fully executed agreement is still being negotiated and will be finalized in the future.  Bassani’s salary will remain $372,000 per year, which will continue to be accrued until there is adequate cash available while negotiations proceed toward the re-instatement of a least a partial cash payment.  Additionally, the Company has agreed to pay him $2,000 per month to be applied to life insurance premiums.  On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025.  The promissory note is secured by Bassani’s $300,000 of January 2015 Convertible Note (Notes 6 and 7) and as of March 31, 2019 the accrued interest was $7,956.

Execution/exercise bonuses:

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods have been reduced to $.01 per option or warrant.

During the year ended June 30, 2014, the Company extended 50% execution/exercise bonuses with the same terms as described above to Schafer and to Jon Northrop (“Northrop”), the Company’s other board member.

During the year ended June 30, 2018, the Company extended 50% execution/exercise bonuses with the same terms as described above to all options and warrants issued prior to November 7, 2017, to an employee and two former employees who are now consultants.

20

During the year ended June 30, 2018, the Company increased the above 50% execution/exercise bonus on all outstanding options and warrants owned or acquired in the future by Bassani, Smith and Schafer to 75% (to the extent such existing exercise bonus is less than 75%).

During the nine months ended March 31, 2019, the Company approved the right to extend the exercise period of all or part of any options or warrants granted in the past or in the future, for up to five years (one year at a time) by annual payments of $0.01 per option/warrant for one of its employees.  The extension payment may be made in i) cash; ii) by reduction of sums owed by the Company, and iii) by reduction of applicable exercise bonuses.

As of March 31, 2019, the execution/exercise bonuses ranging from 50-90% were applicable to 6,934,600 of the Company’s outstanding options and 12,032,095 of the Company’s outstanding warrants.

Litigation:

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and has demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and does not have the resources to make the payment demanded by Pennvest. During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan is now solely an obligation of PA1. No litigation has commenced related to this matter but such litigation is likely if negotiations do not produce a resolution (Notes 1 and Note 5).

The Company currently is not involved in any other material litigation.

9.RELATED PARTY TRANSACTIONS:

The Coalition for Affordable Bay Solutions (“CABS”), a not-for-profit organization that engages in political and legislative lobbying and educational activities regarding the competitive bidding procurement and nutrient credit trading program in Pennsylvania (and elsewhere), shares certain key management members with the Company.  During the year ended June 30, 2017 the Company recorded expenses of $165,650 for consulting costs incurred on behalf of CABS (the Company contributed $68,900 to CABS and issued 129,000 shares of its restricted common stock valued at $96,750 to pay third party consultants for services to CABS) and during the year ended June 30, 2018, the Company received reimbursements from CABS for the prior year expenses of $41,000 incurred by the Company in providing support for CABS.

During the three and nine months ended March 31, 2019, the Company received nil and $30,000 for expense reimbursements from CABS, respectively.  The Company received no expense reimbursements for the three and nine months ended March 31, 2018.  The Company also issued 16,000 shares of its restricted common stock valued at $8,000 for third party consulting expenses on behalf of CABS during the nine months ended March 31, 2019 and paid CABS $12,500 in consulting fees, while there were no such expenses for the nine months ended March 31, 2018.

During the nine months ended March 31, 2019, the Company determined that it had made omissions in not disclosing certain related party transactions with CABS during the years ended June 30, 2018 and 2017.  The Company determined the omissions are immaterial and prior year financial statements and reports previously filed, would not have to be amended.  The Company will disclose comparative prior period disclosures in future filings. 

10.SUBSEQUENT EVENTS:

The Company has evaluated events that occurred subsequent to March 31, 2019 for recognition and disclosure in the financial statements and notes to the financial statements.

From April 1, 2019 through May 8, 2019, the Company has issued 2,734 shares of the Company’s common shares to an employee for services valued at approximately $2,000 and has issued 20,000 shares to a consultant for services valued at approximately $15,000.

From April 1, 2019 through May 8, 2019, the Company has sold 75,000 Units of its securities at $0.50 per Unit for aggregate consideration of $37,500.  Each Unit consists of one share of common stock and a callable warrant to purchase ½ share of the Company’s common shares at $0.75 per share until December 31, 2020.

21

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Statements made in this Form 10-Q that are not historical or current facts, which represent the Company's expectations or beliefs including, but not limited to, statements concerning the Company's operations, performance, financial condition, business strategies, and other information, involve substantial risks and uncertainties.  The Company's actual results of operations, most of which are beyond the Company's control, could differ materially.  These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," anticipate," "estimate," or "continue" or the negative thereof.  We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made.  Any forward looking statements represent management's best judgment as to what may occur in the future.  However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital, unexpected costs, failure (or delay)  to gain product or regulatory approvals in the United States (or particular states) or foreign countries and failure to capitalize upon access to new markets.  Additional risks and uncertainties that may affect forward looking statements about Bion's business and prospects include the possibility that markets for nutrient reduction credits (discussed below) and/or other ways to monetize nutrient reductions will be slow to develop (or not develop at all), the existing default by PA1 on its loan secured by the Kreider 1 system, the possibility that a competitor will develop a more comprehensive or less expensive environmental solution, delays in market awareness of Bion and our Systems, uncertainties and costs related to research and development efforts to update and improve Bion’s technologies and applications thereof, and/or  delays in Bion's development of Projects and failure of marketing strategies, each of which could have both immediate and long term material adverse effects by placing us behind our competitors and requiring expenditures of our limited resources. Bion disclaims any obligation subsequently to revise any forward looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes to Consolidated Financial Statements filed herein with the Company’s Form 10-K for the year ended June 30, 2018.

BUSINESS OVERVIEW

From 2014 through the current 2019 fiscal year, the Company has focused its research and development activities toward development of our 3G Tech, augmenting the basic ‘separate and aggregate’ approach of its technology platform to provide additional flexibility and to increase recovery of nutrient co-products (in organic and non-organic forms) and renewable energy production (either/both biogas and/or renewable electricity and related credits), thereby increasing potential related revenue streams and reducing dependence of its future projects on the monetization of nutrient reductions (which still remain an  important part of project revenue streams). This research and development effort also involves ongoing review of potential “add-ons” and applications to our technology platform for use in different regulatory and/or climate environments. These research and development activities continued through the 2018 fiscal year and into the current 2019 fiscal year with increased focus on recovery of marketable ‘coproducts’ (including nutrients and renewable natural gas) and completion of development of Bion’s 3G Tech and technology platform. We believe such activities will continue at least through the 2019 calendar year (and likely longer), subject to availability of adequate financing for the Company’s operations, of which there is no assurance.  Such activities may include the design and construction of an initial, commercial-scale module utilizing our 3G Tech to assist in optimization efforts before construction of the full Kreider 2 project (see below).

Bion’s 3G Tech and technology platform are designed to capture four revenue streams under one umbrella and provide the basis for joint ventures between the Company and larger livestock producers seeking to produce environmental/sustainable product lines. The revenue streams are: a) renewable energy and associated greenhouse gas credits (including US Renewable Fuel Standard (RFS) and/or Low Carbon Fuel Standard (LCFS) credits), b) verified nutrient reductions (primarily nitrogen) that can be used as qualified offsets to the federal Chesapeake Bay mandate and US EPA TMDL (‘total maximum daily limit’) requirements, c) co-products consisting of high value fertilizer that Bion believes will achieve certification for use in organic food production for human consumption during 2019, and  d) an environmentally sustainable USDA certification that will be incorporated into a “brand” that can address the consumer concerns regarding food safety and sustainability (based on incorporation of all of the third party verified data for greenhouse gas reductions, nutrient reductions and fertilizer products into a digital register).  The “branding” opportunity will offer large scale producer / processor / distributors of livestock products the opportunity to differentiate and identify their products in the marketplace and, thereby creates the opportunity to achieve “premium pricing” by addressing consumer concerns related to safety and sustainability in a manner similar to the premiums achieved by organic producers.

22

Operational results from the initial commercial system (utilizing our 2G Tech) confirmed the ability of Bion’s technologies to meet nutrient reduction goals at commercial scale for an extended period of operation. Bion’s 2G Tech platform (and the new variations under development) center on its patented and proprietary processes that separate and aggregate the various assets in the CAFO waste stream so they become benign, stable and/or transportable. Bion systems can: a) remove up to 95% of the nutrients (primarily nitrogen and phosphorus) in the effluent, b) reduce greenhouse gases by 90% (or more) including elimination of virtually all ammonia emissions, c) while materially reducing pathogens, antibiotics and hormones in the livestock waste stream. In addition to capturing a portion of valuable nutrients for reuse (in organic and/or non-organic forms), Bion’s 2^nd generation technology platform also recovers cellulosic biomass which can be used to generate renewable energy from the waste stream in a process more efficient than other technologies that seek to exploit this CAFO waste stream. Our core technology and its primary CAFO applications are now proven in commercial operations. It has been accepted by the Environmental Protection Agency (“EPA”) and other regulatory agencies and it is protected by Bion’s portfolio of U.S. and international patents (both issued and applied for).

Currently, our research and development activities are underway to improve, update and  commercialization of our 3G Tech systems (which is ready to be implemented) during the current fiscal year to meet the needs of CAFOs in various geographic and climate areas with nutrient release constraints and to increase the recovery and generation of valuable by-products while adding the capability to treat dry (poultry) waste streams in addition to wet manure streams at lower capital costs and operating costs

Bion is focused on using applications of its patented and proprietary waste management technologies and technology platform to pursue three main business opportunities: 1) installation of Bion systems ( some of which may  generate verified nutrient reduction credits and revenues from the production of renewable energy and coproducts) to retrofit and environmentally remediate existing CAFOs (“Retrofits”) in selected markets where: a) government policy supports such efforts (such as the Chesapeake Bay watershed, some Great Lakes Basin states, and/or other states and watersheds facing EPA ‘total maximum daily load’ (“TMDL”) issues, and/or b) where CAFO’s need our technology to obtain permits to expand or develop without negative environmental consequences; 2) development of new state-of-the-art large-scale waste treatment facilities in joint ventures with large CAFO’s in strategic locations (“Projects”) ( some of these may be Integrated Projects) with multiple revenue streams, and 3) licensing and/or joint venturing of Bion’s technology and applications (primarily) outside North America. The opportunities described at 1) and 2) above each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion’s efforts are focused on such political and regulatory matters. Bion intends to pursue international opportunities primarily through the use of consultants with existing relationships in target locations. The most intense focus is currently on the requirements for the clean-up of the Chesapeake Bay faced by the Commonwealth of Pennsylvania and the potential use of Bion’s technology and technology platform on CAFOs to remediate ammonia release (and re-deposition to the ground and water) and as an alternative to what the Company believes is far more expensive nutrient removal downstream in storm water and other projects.

During 2008 the Company commenced actively pursuing the opportunity presented by environmental retrofit and remediation of the waste streams of existing CAFOs which effort has met with very limited success to date. The first commercial activity in this area is represented by our agreement with Kreider Farms (“KF”), pursuant to which the Kreider 1 system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered  full-scale operation during 2011. On January 26, 2009 the Board of the Pennsylvania Infrastructure Investment Authority (“Pennvest”) approved a $7.75 million loan to Bion PA 1, LLC (“PA1”), a wholly-owned subsidiary of the Company, for the initial Kreider Farms project (“Kreider 1 System”). After substantial unanticipated delays, on August 12, 2010 PA1 received a permit for construction of the Kreider 1 System.  Construction activities commenced during November 2010.  The closing/settlement of the Pennvest Loan took place on November 3, 2010.  PA1 finished the construction of the Kreider 1 System and entered a period of system ‘operational shakedown’ during May 2011.  The Kreider 1 System reached full, stabilized operation by the end of the 2012 fiscal year.  During 2011 the PADEP re-certified the nutrient credits for this project.  The PADEP issued final permits for the Kreider 1 System (including the credit verification plan) on August 1, 2012 on which date the Company deemed that the Kreider 1 System was ‘placed in service’.  As a result, PA1 commenced generating nutrient reduction credits for potential sale while continuing to utilize the Kreider 1 System to test improvements and add-ons. However, to date liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth,  which limited liquidity/depth has negatively impacted Bion’s business plans and has resulted in challenges to monetizing the nutrient reductions created by PA1’s existing Kreider 1 project and Bion’s other proposed projects. These difficulties have prevented PA1 from generating any material revenues from the Kreider 1 project to date and raise significant questions as to when, if ever, PA1 will be able to generate such revenues from the Kreider 1 System.  PA1 has had sporadic discussions/negotiations with Pennvest related to forbearance and/or re-structuring its obligations pursuant to the Pennvest Loan for more than three years. In the context of such discussions/negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013.  Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of March 31, 2019.  Due to the failure of the Pennsylvania nutrient reduction credit market to develop, the Company determined that the carrying amount of the property and equipment related to the Kreider 1 project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits and, therefore, PA1 and the Company recorded impairments related to the value of the Kreider 1 assets of $1,750,000 and $2,000,000 at June 30, 2015 and June 30, 2014, respectively.  During the 2016 fiscal year, PA1 and the Company recorded an impairment of $1,684,562 to the value of the Kreider 1 assets which reduced the value on the Company’s books to zero.  This impairment reflects management’s judgment that the salvage value of the Kreider 1 assets roughly equals PA1’s contractual obligations related to the Kreider 1 System, including expenses related to decommissioning of the Kreider 1 System, costs associated with needed capital upgrade expenses, and re-certification/ permitting amendments. See “Impairment loss on property and equipment” below.

23

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and does not have the resources to make the payments demanded by Pennvest. PA1 has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected PA1’s proposal made during the fall of 2014.  As of the date of this report, no formal proposals are currently under consideration and only sporadic communication has taken place regarding the matters involved over the last 48 months.  It is not possible at this date to predict the outcome of this matter, but the Company believes that a loan modification agreement (coupled with an agreement regarding an update and re-start of full operations of KF1) may be reached in the future if/when a more robust market for nutrient reductions develops in Pennsylvania, of which there is no assurance. PA1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days.

The economics (potential revenues, profitability and continued operation) of the Kreider 1 System are based almost entirely on the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. See below for further discussion.

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 System met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been (and is now) solely an obligation of PA1 since that date.

The Company is currently operating the Kreider 1 System in a limited manner pending development of a more robust market for its nutrient reductions.

Bion continues its pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million)(and potentially other poultry operations and/or other waste streams)('Kreider Renewable Energy Facility' or ‘ Kreider 2 Project’).  On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”).During May 2011 the PADEP certified a smaller version of the Kreider 2 Project for 559,457 nutrient credits under the old EPA’s Chesapeake Bay model.  The Company anticipates that when designs are finalized, the Kreider 2 Project will be re-certified for between 1.5-2 million (or more) nutrient reduction credits (for treatment of the waste stream from Kreider’s poultry) pursuant to the Company’s subsequent amended application during the 2019 fiscal year pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA. Note that this Project may be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The review process to clarify certain issues related to credit calculation and verification commenced during 2014 based on Bion’s 2G Tech but has been placed on hold while certain matters are resolved between the EPA and Pennsylvania and pending development of a robust market for nutrient reductions in Pennsylvania. The Company anticipates it will submit an amended application based on our 3G Technology once these matters are clear. Site specific design and engineering work for this facility, which will probably be the first full-scale project to utilize Bion’s 3G Tech, have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2.  If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the 2019 calendar year, and hopes to enter into agreements related to sales of the nutrient reduction credits for future delivery (under long term contracts) during the current 2019 fiscal year subject to verification by the PADEP based on operating data from the Kreider 2 Project. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its use of Bion’s 3G Tech for increased recovery of marketable by-products, are based in material part the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up.  However, liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and has resulted in challenges to monetizing the nutrient reduction credits generated by PA1’s existing Kreider 1 project and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

24

Note that while Bion believes that the Kreider 1 System, the Kreider 2 Project and/or subsequent Bion Projects will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees related to a ‘sustainable brand’.  We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

A substantial portion of our activities involve public policy initiatives (by the Company and other stakeholders) to encourage the establishment of appropriate public policies and regulations (at federal, regional, state and local levels) to facilitate cost effective environmental clean-up and, thereby, support our business activities. Bion has been joined by National Milk Producers Federation, Land O’Lakes, JBS and other national livestock interests to support changes to our nation’s clean water strategy that will allow states to acquire low-cost nutrient reductions through a competitive procurement process, in a similar manner to how government entities now acquire many other goods and services on behalf of the taxpayer. As developing markets for nutrient reductions become fully-established, Bion anticipates a robust business opportunity to retrofit existing CAFOs and develop Projects, based primarily on the sale of nutrient credits that provide cost-effective alternatives to today’s high-cost and failing clean water strategy.

To date the market for long-term nutrient reduction credits in Pennsylvania (‘PA’) has been very slow to develop and the Company’s activities have been negatively affected by such lack of development.  However, Bion is confident that once these markets are established, the credits it produces will be competitive in the credit trading markets, based on its cost to remove nitrogen from the livestock waste stream, compared to the cost to remove nitrogen through various other treatment activities.

Several independent studies have calculated the average cost to remove nitrogen through various sector practices. Reports prepared for the PA Senate (2008), Chesapeake Bay Commission (2012) and PA legislature (2013; described below), as well as the Maryland Chesapeake Bay Financing Strategy Report (2015), demonstrate that the cost to remove nitrogen (per pound on average) from agriculture is $44 to $54, municipal wastewater: $28 to $43, and storm water: $386 to $633. Pursuant to the PA legislative Report, by replacing sector allocation (for all sectors) with competitive bidding, up to 80 percent savings could be achieved in PA’s Chesapeake Bay compliance costs ($1.5 billion annually) by 2025. If the legislative study had focused on the cost differentials of competitive bidding compared only with storm water, the relative savings would be substantially greater.

Since these studies were completed, most of the larger (Tier 1) municipal wastewater treatment plants in PA have been upgraded, at a cost of approximately $2.5 billion (vs initial 2004 PA DEP cost estimates of $376 million). US EPA is now focused on PA’s storm water allocation (3.5 million pounds (per last published data)) and has this sector on ‘backstop level actions’, the highest level of EPA-oversight and the final step before sanctions. In the same 2004 PA DEP cost estimate that led to the more than a $2 billion underestimate/miscalculation in municipal wastewater plant upgrade costs, the estimate for storm water cost was $5.6 billion. In April 2017, US EPA sent a Letter of Expectation to PA DEP, expressing the agency’s support for the use of nutrient credit trading and competitive bidding to engage the private-sector to lower costs. The letter specifically encouraged the use of credit trading to offset the state’s looming storm water obligations.

The Company believes that: i)  the April 2015 release of a report from the Pennsylvania Auditor General titled “Special Report on the Importance of Meeting Pennsylvania’s Chesapeake Bay Nutrient Reduction Targets” which highlighted the economic consequences of EPA-imposed sanctions if the state fails to meet the 2017 TMDL targets, as well as the need to support using low-cost solutions and technologies as alternatives to higher-cost public infrastructure projects, where possible, and ii)   Senate Bill 575 (introduced in April, 2019 as successor to prior SB 799 which  was passed by a 47-2 vote in the PA Senate during January 2018 but was not voted on in the House)) which, if adopted, will establish a program that will allow the Pennsylvania’s tax- and rate-payers to meet significant portions of their EPA-mandated Chesapeake Bay pollution reductions at significantly lower cost by purchasing verified reductions (by competitive bidding) from all sources, including those that Bion can produce through livestock waste treatment, represent visible evidence of progress being made on these matters in Pennsylvania. Such legislation (which has bi-partisan support), if passed and signed into law (of which there is no assurance), will potentially enable Bion (and others) to compete for public funding on an equal basis with subsidized agricultural ‘best management practices’ and public works and storm water authorities. Note, however, that there was opposition to SB 799 (and its predecessors) from threatened stakeholders committed to the existing status quo approaches--- a significant portion of which was focused on attacking (in often inaccurate and/or vilifying ways) Bion in/through social media and internet articles, blogs, press releases, twitter posts and re-tweets, rather than engaging the substantive issues. If legislation similar to SB 575 is passed (on a stand-alone basis or as part of a larger piece of legislation) and implemented (in a form which maintains its core provisions), Bion expects that the policies and strategies being developed in PA will not only benefit the Company’s existing and proposed PA projects, but will also subsequently provide the basis for a larger Chesapeake Bay watershed strategy and, thereafter, a national clean water strategy.

The Company believes that Pennsylvania is ‘ground zero’ in the long-standing clean water battle between agriculture and the further regulation of agriculture relative to nutrient impacts. The ability of Bion and other technology providers to achieve verified reductions from agricultural non-point sources can resolve the current stalemate and enable implementation of constructive solutions that benefit all stakeholders, providing a mechanism that ensures that taxpayer funds will be used to achieve the most beneficial result at the lowest cost, regardless of source. All sources, point and non-point, rural and urban, will be able to compete for tax payer-funded nitrogen reductions in a fair and transparent process; and since payment from the tax and rate payers would now be performance-based, these providers will be held financially accountable.

25

We believe that the overwhelming environmental, economic, quality of life and public health benefits to all stakeholders in the watershed, both within and outside of Pennsylvania, make the case for adoption of the strategies outlined in the Report less an issue of ‘if’, but of ‘when and how’. The adoption of a competitive procurement program will have significant positive impact on technology providers that can deliver verified nitrogen reductions such as Bion, by allocating existing tax- and rate-payer clean water funding to low cost solutions based upon a voluntary and transparent procurement process. The Company believes that implementation of a competitively-bid nutrient reduction program to achieve the goals for the Chesapeake Bay watershed can also provide a working policy model and platform for other states to adopt that will enhance their efforts to comply with both current and future requirements for local and federal estuarine watersheds, including the Mississippi River/Gulf of Mexico, the Great Lakes Basin and other nutrient-impaired watersheds.

Bion will also pursue the opportunities related to development of Projects, including Integrated Projects which are likely to involve joint ventures with large livestock producers who can utilized the benefits of the ‘sustainable branding’ that Bion intends to enable for products produced utilizing its technology).  Integrated Projects will include large CAFOs (such as large poultry facilities, dairy complexes, beef cattle feed lots and/or hog farms) with Bion waste treatment/resource recovery  system modules processing the aggregate CAFO waste stream from the equivalent of 20,000 to 80,000 (or more) beef or dairy cows (or the waste stream equivalent of other species), while recovering renewable energy and value-added fertilizer/soil amendment products, integrated with CAFO end product users/processing facilities, and/or potentially in some locations, a biofuel/ethanol plant.. Such Integrated Projects will involve large CAFOs with Bion waste treatment/resource recovery modules on a single site and/or on sites within an approximately 30-mile radius.  Bion believes its 3G technology platform will allow integration of large-scale CAFO's with end product processors (and/or potentially biofuel production), together with renewable energy production and co-product recovery from the waste streams, and on-site energy utilization in a relatively 'closed loop' manner that will reduce the capital expenditures, operating costs and carbon footprint for the entire Integrated Project and each component facility. Some Integrated Projects may be developed from scratch while others may be developed in geographic proximity to (and in coordination with) existing participating CAFOs, end product processors and/or biofuel plants. Each Integrated Project is likely to have different degrees of integration, especially in the early development phases.

The Company currently anticipates that the Kreider 2 poultry waste treatment facility in PA will be its initial full-scale 3G Project. Bion anticipates that it will finalize site selection for the Kreider 2 Project and/or its initial Integrated Project (and possibly additional Projects) during the current fiscal year. Bion hopes to commence development of its initial Project by optioning land and beginning the site-specific design and permitting process during calendar year 2019, but further delays are possible. It is not possible at this time to firmly predict where the initial Project will be developed or the order in which Projects will be developed. All potential Projects are in very early discussion and pre-development stages and may never progress to actual development or may be developed after other Projects not yet under active consideration.

Bion also hopes to be able to move forward on additional Projects through 2020-22 to create a pipeline of Projects. Management has a 5-year development target (through calendar year 2023) of approximately 10 or more Projects pursuant to joint ventures (or similar agreements). Management hopes to have identified and begun development work related to 3-5 Projects over the next 2 years. At the end of the 5-year period, Bion projects that 3-8 of these Projects will be in full operation in 3-6 states (and possibly one or more foreign countries), and the balance would be in various stages ranging from partial operation to early development stage. It is possible that one or more Projects will be developed in joint ventures specifically targeted to meet the growing animal protein demand outside of the United States (including without limitation Asia, Europe and/or the Middle East). No Projects (including Integrated Projects) have been developed to date.

The Company’s audited financial statements for the years ended June 30, 2018 and 2017 have been prepared assuming the Company will continue as a going concern. The Company has incurred net losses of approximately $3,018,000 and $2,463,000 during the years ended June 30, 2018 and 2017, respectively. The Report of the Independent Registered Public Accounting Firm on the Company’s consolidated financial statements as of and for the year ended June 30, 2018 includes a “going concern” explanatory paragraph which means that the accounting firm has reported substantial doubt about the Company’s ability to continue as a going concern.  The Company has incurred net losses of approximately $1,951,000 and $2,771,000 for the nine months ended March 31, 2019 and 2018, respectively.  At March 31, 2019, the Company had a working capital deficit and a stockholders’ deficit of approximately $10,623,000 and $14,290,000, respectively. Management’s plans with respect to these matters are described in this section and in our consolidated financial statements (and notes thereto), and this material does not include any adjustments that might result from the outcome of this uncertainty. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

26

CRITICAL ACCOUNTING POLICIES

Revenue Recognition

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

Derivative Financial Instruments:

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

Warrants:

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

Recent Accounting Pronouncements:

In May 2017, the FASB issued ASU No. 2017-09 “Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications.  The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications.  ASU No. 2017-09 will be applied prospectively to awards modified on or after the adoption date.  The guidance is effective for annual periods, and interim periods within those annual periods beginning December 15, 2017, with early adoption permitted.  The Company does not anticipate any material impact on the Company’s financial statements upon adoption.

THREE MONTHS ENDED MARCH 31, 2019 COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2018

Revenue

Total revenues were nil for both the three months ended March 31, 2019 and 2018, respectively.

General and Administrative

Total general and administrative expenses were $305,000 and $957,000 for the three months ended March 31, 2019 and 2018, respectively.

General and administrative expenses, excluding stock-based compensation charges of $5,000 and $691,000, were $300,000 and $266,000 for the three months ended March 31, 2019 and 2018, respectively, representing a $34,000 increase.  Salaries and related payroll tax expenses decreased slightly from $72,000 for the three months ended March 31, 2018 to $62,000 for the three months ended March 31, 2019 due to one less employee during the three months ended March 31, 2019.  Consulting costs were $115,000 and $103,000 for the three months ended March 31, 2019 and 2018, respectively, representing a $12,000 increase.  Consulting costs were higher during the three months ended March 31, 2019 due to payments for governmental affairs consulting related to Chesapeake Bay legislation. Investor relations expenses were $44,000 and $7,000 for the three months ended March 31, 2019 and 2019, respectively.  The increase in investor relations is due to a new contract with a company providing investor relations for emerging growth companies during the three months ended March 31, 2019.

27

General and administrative stock-based employee compensation for the three months ended March 31, 2019 and 2018 consists of the following:

	Three months ended March 31, 2019		Three months ended March 31, 2018
General and administrative:
Fair value of stock/warrant bonus expensed	$	-	$	2,000
Change in fair value from modification of warrant terms		-		7,000
Fair value of stock options expensed under ASC 718		5,000		682,000
Total	$	5,000	$	691,000

Stock-based compensation charges were $5,000 and $691,000 for the three months ended March 31, 2019 and 2018, respectively.  Compensation expense relating to stock/warrant bonuses expensed for the three months ended March 31, 2019 and 2018 of nil and $2,000, respectively, primarily related to 100,000 shares in stock bonuses granted to an employee and a consultant with vesting periods ranging from April 2017 through January 2020 (a portion of which were allocated to research and development) which were cancelled in fiscal year 2018.  During the three months ended March 31, 2018, the Company extended expiration dates of warrants for an employee which resulted in the recognition of $7,000 in non-cash compensation, while no warrants were modified during the three months ended March 31, 2019 other to investors which were recorded as interest expense.  The fair value of stock options expensed for the three months ended March 31, 2019 and 2018 was $5,000 and $682,000 respectively.  The Company granted 25,000 and 2,352,500 fully vested options during the three months ended March 31, 2019 and 2018, respectively.

Depreciation

Total depreciation expense was $271 and $436 for the three months ended March 31, 2019 and 2018, respectively.

Research and Development

Total research and development expenses were $104,000 and $680,000 for the three months ended March 31, 2019 and 2018, respectively.

Research and development expenses, excluding stock-based compensation expenses of nil and $587,000 were $104,000 and $93,000 for the three months ended March 31, 2019 and 2018, respectively, representing a $11,000 increase.  Salaries and related payroll tax expenses were $20,000 and $16,000 for the three months ended March 31, 2019 and 2018, respectively.  Consulting costs were $16,000 and $3,000 for the three months ended March 31, 2019 and 2018, respectively, and the increase is attributable to cost incurred to determine how to proceed with a future pilot program. 

Research and development stock-based employee compensation for the three months ended March 31, 2019 and 2018 consists of the following:

	Three months ended March 31, 2019		Three months ended March 31, 2018
Research and development:
Fair value of stock bonuses expensed under ASC 718	$	-	$	587,000
Total	$	-	$	587,000

Stock-based compensation expenses were nil and $587,000 for the three months ended March 31, 2019 and 2018, respectively.    During the three months ended March 31, 2018, the Company granted 2,352,500 options that were fully vested, a portion of which was allocated to research and development employees and consultants.  During the three months ended March 31, 2019, no options were granted to research and development employees.

Loss from Operations

As a result of the factors described above, the loss from operations was $409,000 and $1,638,000 for the three months ended March 31, 2019 and 2018, respectively.

Other Expense

Other expense was $100,000 and $93,000 for the three months ended March 31, 2019 and 2018, respectively.   Interest expense was $100,000 and $85,000 for the three months ended March 31, 2019 and 2018, respectively.    The increase of $15,000 is primarily due to higher interest on the Pennvest loan and deferred compensation balances for the three months ended March 31, 2019.  The Company recorded a conversion inducement expense of $8,000 during the three months ended March 31, 2018 due to a limited time offer to reduce the exercise price of certain warrants.

28

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was $505 and $1,472 for the three months ended March 31, 2019 and 2018, respectively.

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net loss attributable to Bion’s common stockholders was $509,000 and $1,729,000 for the three months ended March 31, 2019 and 2018, respectively, and the net loss per basic common share was $0.01 and $0.07 for the three months ended March 31, 2019 and 2018, respectively.

NINE MONTHS ENDED MARCH 31, 2019 COMPARED TO THE NINE MONTHS ENDED MARCH 31, 2018

Revenue

Total revenues were nil for both the nine months ended March 31, 2019 and 2018, respectively.

General and Administrative

Total general and administrative expenses were $1,273,000 and $2,078,000 for the nine months ended March 31, 2019 and 2018, respectively.

General and administrative expenses, excluding stock-based compensation charges of $426,000 and $1,199,000, were $847,000 and $879,000 for the nine months ended March 31, 2019 and 2018, respectively, representing a $32,000 decrease.  Salaries and related payroll tax expenses were $193,000 and $218,000 for the nine months ended March 31, 2019 and 2018, respectively, representing a $25,000 decrease due to one less employee during the nine months ended March 31, 2019.  Consulting costs were $318,000 and $364,000 for the nine months ended March 31, 2019 and 2018, respectively.  The reduction in consulting costs is due to costs related to one consultant being allocated to research and development that was previously general and administrative and other reduced utilization of consultants during the nine months ended March 31, 2019.  Insurance related expenses were $64,000 and $50,000 for the nine months ended March 31, 2019 and 2018, respectively, as the Company economized by changing some of its insurance coverage during the nine months ended March 31, 2018 but then increased coverage again during the nine months ended March 31, 2019.

General and administrative stock-based employee compensation for the nine months ended March 31, 2019 and 2018 consists of the following:

	Nine months ended March 31, 2019		Nine months ended March 31, 2018
General and administrative:
Fair value of stock bonus expensed	$	-	$	9,000
Change in fair value from modification of option terms		211,000		244,000
Change in fair value from modification of warrant terms		118,000		164,000
Fair value of stock options expensed under ASC 718		97,000		782,000
Total	$	426,000	$	1,199,000

Stock-based compensation charges were $426,000 and $1,199,000 for the nine months ended March 31, 2019 and 2018, respectively.  Compensation expense relating to stock bonuses expensed for the nine months ended March 31, 2018 of $9,000, related to 100,000 shares in stock bonuses granted to an employee and a consultant with vesting periods ranging from April 2017 through January 2020 (a portion of which were allocated to research and development).  Compensation expense relating to the change in fair value from the modification of option terms was $211,000 and $244,000 for the nine months ended March 31, 2019 and 2018, respectively, as the Company granted a reduction in certain exercise prices and an extension of certain option expiration dates for an employee during the nine months ended March 31, 2019 and the Company extended certain option expiration dates for seven employees and consultants during the nine months ended March 31, 2018.During the nine months ended March 31, 2019 and 2018, respectively, the Company extended expiration dates of warrants for certain employees and consultants which resulted in the recognition of $118,000 and $164,000, respectively, in non-cash compensation.  The fair value of stock options expensed for the nine months ended March 31, 2019 and 2018 was $97,000 and $782,000 respectively.   The Company granted 350,000 and 2,647,500 fully vested options during the nine months ended March 31, 2019 and 2018, respectively.

29

Depreciation

Total depreciation expense was $966 and $1,308 for the nine months ended March 31, 2019 and 2018, respectively.

Research and Development

Total research and development expenses were $387,000 and $1,126,000 for the nine months ended March 31, 2019 and 2018, respectively.

Research and development expenses, excluding stock-based compensation expenses of $82,000 and $841,000 were $305,000 and $285,000 for the nine months ended March 31, 2019 and 2018, respectively, representing a $20,000 increase.  Salaries and related payroll tax expenses were $60,000 and $52,000 for the nine months ended March 31, 2019 and 2018, respectively.  Consulting costs were $177,000 and $154,000 for the nine months ended March 31, 2019 and 2018, respectively. 

Research and development stock-based employee compensation for the nine months ended March 31, 2019 and 2018 consists of the following:

	Nine Months ended March 31, 2019		Nine Months ended March 31, 2018
Research and development:
Fair value of stock bonuses expensed	$	-	$	15,000
Change in fair value from modification of option terms		11,000		106,000
Change in fair value from modification of warrant terms		45,000		133,000
Fair value of stock options expensed under ASC 718		26,000		587,000
Total	$	82,000	$	841,000

Stock-based compensation expenses were $82,000 and $841,000 for the nine months ended March 31, 2019 and 2018, respectively.    Compensation expense relating to stock bonuses expensed for the nine months ended March 31, 2018 of $15,000 related to 70,000 shares in stock bonuses granted to an employee, whose time is partially allocated to research and development, with vesting periods ranging from April 2017 through January 2020.  The compensation expense of $11,000 and $106,000 for the nine months ended March 31, 2019 and 2018, respectively, for the change in fair value from modification of options terms is due to a research and development employee and consultant having certain option exercise prices reduced during those periods.    During both the nine months ended March 31, 2019 and 2018, the Company extended expiration dates of warrants for certain research and development employees and consultants which resulted in the recognition of $45,000 and $133,000, respectively, in non-cash compensation.  The Company expensed $26,000 and $587,000 for the fair value of stock options that vested during the nine months ended March 31, 2019 and 2018, respectively.  The Company granted 350,000 and 2,647,500 options during the nine months ended March 31, 2019 and 2018, respectively, that were fully vested within that time period and a portion of the stock compensation was allocated to research and development.

Loss from Operations

As a result of the factors described above, the loss from operations was $1,661,000 and $3,205,000 for the nine months ended March 31, 2019 and 2018, respectively.

Other Expense (Income)

Other expense (income) was $290,000 and  $(434,000) for the nine months ended March 31, 2019 and 2018, respectively.  During the nine months ended March 31, 2018, the Company recognized other income of $719,000 due to the extinguishment of liabilities related to deferred compensation of non-related parties.  Interest expense was $290,000 and $277,000 for the nine months ended March 31, 2019 and 2018, respectively.  Interest expense related to the Pennvest loan increased by $25,000 during the nine months ended March 31, 2019 but it was partially offset by lower interest on deferred compensation due to lower average balances owed during the nine months ended March 31, 2019.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was $4,000 and $2,000 for the nine months ended March 31, 2019 and 2018, respectively.

30

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net loss attributable to Bion’s stockholders was $1,947,000 and $2,769,000 for the nine months ended March 31, 2019 and 2018, respectively, and the net loss per basic common share was $0.07 and $0.11 for the nine months ended March 31, 2019 and 2018, respectively.

LIQUIDITY AND CAPITAL RESOURCES

The Company's consolidated financial statements for the nine months ended March 31, 2019 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's consolidated financial statements as of and for the year ended June 30, 2018 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

Operating Activities

As of March 31, 2019, the Company had cash of approximately $149,000. During the nine months ended March 31, 2019, net cash used in operating activities was $609,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance and legal and accounting expenses. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

Investing Activities

During the nine months ended March 31, 2019, the Company had investing activities of $2,000 for the purchase of property and equipment.

Financing Activities

During the nine months ended March 31, 2019, the Company received cash proceeds of $792,000 from the sale of 1,584,733 units which consists of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share through dates ranging from June 30, 2019 to December 2020.  The Company paid cash commissions related to the sale of units of $53,000.

As of March 31, 2019 the Company has debt obligations consisting of: a) deferred compensation of $844,000, b) convertible notes payable – affiliates of $3,619,000, and, c) a loan payable and accrued interest of $9,228,000 (owed by PA1).

Plan of Operations and Outlook

As of March 31, 2019, the Company had cash of approximately $149,000.

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During the past five years (fiscal years 2014 through 2018), the Company experienced greater difficulty in raising equity and debt funding than in the prior years (which is not mitigated by the relative increase in equity funding during the nine months ended March 31, 2019). As a result, the Company faced, and continues to face, significant cash flow management challenges due to material working capital constraints. These difficulties, challenges and constraints have continued during fiscal years 2017 and 2018 and the Company anticipates that they may continue for the next twelve (12) months or longer. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 4 and 6 to Financial Statements) and members of the Company's senior management have made loans to the Company which have been converted into convertible promissory notes as of March 31, 2019. During the year ended June 30, 2018 senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000.  As of March 31, 2019, such deferrals totaled approximately $4,463,000 (including accrued interest and deferred compensation converted into promissory notes but excluding conversions of deferred compensation into the Company's common stock by officers, employees and consultants that have already been completed). The extended constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company's effort to develop its business. The Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again in 2018. The Company has had to delay payments of trade obligations and economize in many ways that have potentially negative consequences. If the Company does not have greater success in its efforts to raise needed funds during the current year (and subsequent periods), we will need to consider deeper cuts (including additional personnel cuts) and curtailments of operations (including possibly Kreider 1 operations). The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including Integrated Projects) and CAFO Retrofit waste remediation systems (including the Kreider 2 facility) and to continue to operate the Kreider 1 facility (subject to agreements being reached with Pennvest as discussed above). The Company anticipates that it will seek to raise from $2,500,000 to $50,000,000 or more (debt and equity) during the next twelve months. However, as discussed above, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

31

The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. During the nine months ended March 31, 2019 the Company raised gross proceeds of approximately $792,000 through the sale of its securities (Note 7 to the annual Financial Statements in the Form 10-Q) and paid commissions of approximately $53,000, and anticipates raising additional funds from such sales and transactions. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

Because the Company is not currently generating significant revenues, the Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects and to sustain operations at the KF 1 facility.

The first commercial activity in the Retrofit segment is represented by our agreement with Kreider Farms ("KF"), pursuant to which the Kreider 1 system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered  full-scale operation during 2011. On January 26, 2009 the Board of the Pennsylvania Infrastructure Investment Authority ("Pennvest") approved a $7.75 million loan to Bion PA 1, LLC ("PA1"), a wholly-owned subsidiary of the Company, for the initial Kreider Farms project ("Kreider 1 System"). After substantial unanticipated delays, on August 12, 2010 PA1 received a permit for construction of the Kreider 1 system.  Construction activities commenced during November 2010.  The closing/settlement of the Pennvest Loan took place on November 3, 2010.  PA1 finished the construction of the Kreider 1 System and entered a period of system 'operational shakedown' during May 2011.  The Kreider 1 System reached full, stabilized operation by the end of the 2012 fiscal year.  During 2011 the PADEP re-certified the nutrient credits for this project.  The PADEP issued final permits for the Kreider 1 System (including the credit verification plan) on August 1, 2012 on which date the Company deemed that the Kreider System was 'placed in service'.  As a result, PA1 commenced generating nutrient reduction credits for potential sale while continuing to utilize the Kreider 1 system to test improvements and add-ons. However, to date liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth,  which limited liquidity/depth has negatively impacted Bion's business plans and has resulted in challenges to monetizing the nutrient reductions created by PA1's existing Kreider 1 project and Bion's other proposed projects. These difficulties have prevented PA1 from generating any material revenues from the Kreider 1 project to date and raise significant questions as to when, if ever, PA1 will be able to generate such revenues from the Kreider 1 system.  PA1 has had sporadic discussions/negotiations with Pennvest related to forbearance and/or re-structuring its obligations pursuant to the Pennvest Loan for more than three years. In the context of such discussions/negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013.  Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of March 31, 2019.  Due to the failure of the PA nutrient reduction credit market to develop, the Company determined that the carrying amount of the property and equipment related to the Kreider 1 project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits and, therefore, PA1 and the Company recorded impairments related to the value of the Kreider 1 assets of $1,750,000 and $2,000,000 at June 30, 2015 and June 30, 2014, respectively.  During the 2016 fiscal year, PA1 and the Company recorded an impairment of $1,684,562 to the value of the Kreider 1 assets which reduced the value on the Company's books to zero.  This impairment reflects management's judgment that the salvage value of the Kreider 1 assets roughly equals PA1's contractual obligations related to the Kreider 1 system, including expenses related to decommissioning of the Kreider 1 system, costs associated with needed capital upgrade expenses, and re-certification/ permitting amendments. See "Impairment loss on property and equipment" above.

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and does not have the resources to make the payments demanded by Pennvest. PA1 has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected PA1's proposal made during the fall of 2014.  As of the date of this report, no formal proposals are currently under consideration and only sporadic communication has taken place regarding the matters involved over the last 48 months.  It is not possible at this date to predict the outcome of this matter, but the Company believes that a loan modification agreement (coupled with an agreement regarding an update and restart of full operations of KF1) may be reached in the future if/when a more robust market for nutrient reductions develops in PA, of which there is no assurance. PA1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days.

32

The economics (potential revenues, profitability and continued operation) of the Kreider 1 System are based almost entirely on the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. See below for further discussion.

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the 'technology guaranty' standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan is now solely an obligation of PA1.

The Company is currently operating the Kreider 1 System in a limited manner pending development of a more robust market for its nutrient reductions.

As indicated above, the Company anticipates that it will seek to raise from $2,500,000 to $50,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects and other activities, continue its technology development and/or to successfully develop its business.

There is extremely limited likelihood that funds required during the next twelve months or in the periods immediately thereafter will be generated from operations and there is no assurance that those funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for companies such as Bion.

Currently, Bion is focused on using applications of its patented and proprietary waste management technologies and technology platform to pursue three main business opportunities: 1) installation of Bion systems ( some of which may  generate verified nutrient reduction credits and revenues from the production of renewable energy and byproducts) to retrofit and environmentally remediate existing CAFOs ("Retrofits") in selected markets where: a) government policy supports such efforts (such as the Chesapeake Bay watershed, Great Lakes Basin states, and/or other states and watersheds facing EPA 'total maximum daily load' ("TMDL") issues, and/or b) where CAFO's need our technology to obtain permits to expand or develop without negative environmental consequences; 2) development of new state-of-the-art large scale waste treatment facilities in joint ventures with large CAFO’s in strategic locations ("Projects") ( some of these may be Integrated Projects as described below) with multiple revenue streams, and 3) licensing and/or joint venturing of Bion's technology and applications (primarily) outside North America commencing during the 2019 calendar year. The opportunities described at 1) and 2) above each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion's efforts are focused on such political and regulatory matters. Bion is currently pursuing the international opportunities primarily through the use of consultants with existing relationships in target countries. The most intense focus is currently on the requirements for the clean-up of the Chesapeake Bay faced by the Commonwealth of Pennsylvania and the potential use of Bion’s technology and technology platform on CAFOs to remediate ammonia release (and re-deposition to the ground and water) and as an alternative to what the Company believes is far more expensive nutrient removal downstream in storm water and other projects.

33

Additionally, the Kreider agreements provide for Bion to develop a waste treatment/renewable energy production facility to treat the waste from Kreider's approximately 6+ million chickens (planned to expand to approximately 9-10 million)(and potentially other poultry operations and/or other waste streams)('Kreider Renewable Energy Facility' or ' Kreider 2 Project').  On May 5, 2016, the Company executed a stand-alone joint venture agreement with Kreider Farms covering all matters related to development and operation of a system to treat the waste streams from Kreider's poultry facilities in Bion PA2 LLC ("PA2"). The Company continues its development work related to the details of the Kreider 2 Project. During May 2011 the PADEP certified Kreider 2 Project for 559,457 nutrient credits under the old EPA's Chesapeake Bay model.  The Company anticipates that the Kreider 2 Project will be re-certified for between 1.5-2 million (or more) nutrient reduction credits (for treatment of the waste stream from Kreider's poultry) pursuant to the Company's pending reapplication (or subsequent amended application) during 2018 pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA. Note that this Project may be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy – including the Kreider Dairy) and/or Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The review process to clarify certain issues related to credit calculation and verification commenced during 2014 based on Bion’s 2G Tech but has been largely placed on hold while certain matters are resolved between the EPA and PA and pending development of a robust market for nutrient reductions in PA. The Company anticipates it will submit an amended application based on our 3G Technology once these matters are clear. Site specific design and engineering work for this facility, which will probably be the first full-scale project to utilize Bion's 3G Tech,  have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in PA, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status of its initial modules during the 2019 calendar year, and hopes to enter into agreements related to sales of the nutrient reduction credits for future delivery (under long term contracts) during the 2019 fiscal year subject to verification by the PADEP based on operating data from the Kreider 2 Project. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its use of Bion's 3G Tech for increased recovery of marketable by-products, are based in material part the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up.  However, liquidity in the PA nutrient credit market has been slow to develop significant breadth and depth, which lack of liquidity has negatively impacted Bion's business plans and has resulted in challenges to monetizing the nutrient reduction credits generated by PA1's existing Kreider 1 project and will most likely delay PA2's Kreider 2 Project and other proposed projects in PA.

Note that while Bion believes that the Kreider 1 System, the Kreider 2 Project and/or subsequent Bion Projects will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees related to a ‘sustainable brand’. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

The Company anticipates that the Kreider 2 poultry waste treatment facility in PA will be its initial Project. Bion anticipates that it will select a site for the Kreider 2 Project and/or its initial Integrated Project (and possibly additional Projects) during the current fiscal year. Bion hopes to commence development of its initial Project by optioning land and beginning the site specific design and permitting process during 2019, but delays are possible. It is not possible at this time to firmly predict where the initial Project will be developed or the order in which Projects will be developed. All potential Projects are in very early pre-development stages and may never progress to actual development or may be developed after other Projects not yet under active consideration.

Bion also hopes to be able to move forward on additional Projects through 2019-22 to create a pipeline of Projects. Management has a 5-year development target (through calendar year 2023) of approximately 10 or more Projects. Management hopes to have identified and begun development work related to 3-5 Projects over the next 2 years. At the end of the 5-year period, Bion projects that 3-8 of these Projects will be in full operation in 3-6 states (and possibly one or more foreign countries), and the balance would be in various stages ranging from partial operation to early development stage. It is possible that one or more Projects will be developed in joint ventures specifically targeted to meet the growing animal protein demand outside of the United States (including without limitation Asia, Europe and/or the Middle East). No Projects (including Integrated Projects) has been developed to date.

34

CONTRACTUAL OBLIGATIONS

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

During 2008 the Company commenced actively pursuing the opportunity presented by environmental retrofit and remediation of the waste streams of existing CAFOs which effort has met with very limited success to date. The first commercial activity in this area is represented by our agreement with Kreider Farms ("KF"), pursuant to which the Kreider 1 system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered  full-scale operation during 2011. On January 26, 2009 the Board of the Pennsylvania Infrastructure Investment Authority ("Pennvest") approved a $7.75 million loan to Bion PA 1, LLC ("PA1"), a wholly-owned subsidiary of the Company, for the initial Kreider Farms project ("Kreider 1 System"). After substantial unanticipated delays, on August 12, 2010 PA1 received a permit for construction of the Kreider 1 system.  Construction activities commenced during November 2010.  The closing/settlement of the Pennvest Loan took place on November 3, 2010.  PA1 finished the construction of the Kreider 1 System and entered a period of system 'operational shakedown' during May 2011.  The Kreider 1System reached full, stabilized operation by the end of the 2012 fiscal year.  During 2011 the PADEP re-certified the nutrient credits for this project.  The PADEP issued final permits for the Kreider 1 System (including the credit verification plan) on August 1, 2012 on which date the Company deemed that the Kreider System was 'placed in service'.  As a result, PA1 commenced generating nutrient reduction credits for potential sale while continuing to utilize the Kreider 1 system to test improvements and add-ons. However, to date liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth,  which limited liquidity/depth has negatively impacted Bion's business plans and has resulted in challenges to monetizing the nutrient reductions created by PA1's existing Kreider 1 project and Bion's other proposed projects. These difficulties have prevented PA1 from generating any material revenues from the Kreider 1 project to date and raise significant questions as to when, if ever, PA1 will be able to generate such revenues from the Kreider 1 system.  PA1 has had sporadic discussions/negotiations with Pennvest related to forbearance and/or re-structuring its obligations pursuant to the Pennvest Loan for more than three years. In the context of such discussions/negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013.  Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of March 31, 2019.  Due to the failure of the PA nutrient reduction credit market to develop, the Company determined that the carrying amount of the property and equipment related to the Kreider 1 project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits and, therefore, PA1 and the Company recorded impairments related to the value of the Kreider 1 assets of $1,750,000 and $2,000,000 at June 30, 2015 and June 30, 2014, respectively.  During the 2016 fiscal year, PA1 and the Company recorded an impairment of $1,684,562 to the value of the Kreider 1 assets which reduced the value on the Company's books to zero.  This impairment reflects management's judgment that the salvage value of the Kreider 1 assets roughly equals PA1's contractual obligations related to the Kreider 1 system, including expenses related to decommissioning of the Kreider 1 system, costs associated with needed capital upgrade expenses, and re-certification/ permitting amendments. See "Impairment loss on property and equipment" above.

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and does not have the resources to make the payments demanded by Pennvest. PA1 has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected PA1's proposal made during the fall of 2014.  As of the date of this report, no formal proposals are currently under consideration and only sporadic communication has taken place regarding the matters involved over the last 48 months.  It is not possible at this date to predict the outcome of this matter, but the Company believes that a loan modification agreement (coupled with an agreement regarding an update and restart of full operations of KF1) may be reached in the future if/when a more robust market for nutrient reductions develops in PA, of which there is no assurance. PA1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days.

The economics (potential revenues, profitability and continued operation) of the Kreider 1 System are based almost entirely on the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up.

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the 'technology guaranty' standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan is now solely an obligation of PA1.

The Company is currently operating the Kreider 1 System in a limited manner pending development of a more robust market for its nutrient reductions.

35

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S‑K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4.  Controls and Procedures.

(a)  Evaluation of Disclosure Controls and Procedures.

The term "disclosure controls and procedures" is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized, and reported within the required time periods. Our Chief Executive Officer and Principal Financial Officer has evaluated the effectiveness of the design and operations of our disclosure controls and procedures as of the end of the period covered by this quarterly report, and has concluded that, as of that date, our disclosure controls and procedures were not effective at ensuring that required information will be disclosed on a timely basis in our reports filed under the Exchange Act, as a result of the material weakness in internal control over financial reporting discussed in Item 9(A) of our Form 10-K for the year ended June 30, 2018.

(b)  Changes in Internal Control over Financial Reporting.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

36

PART II – OTHER INFORMATION

Item 1.  Legal Proceedings.

On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and has demanded that our wholly-owned subsidiary Bion PA-1 LLC (‘PA-1’) pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. The Company anticipates that it is possible that discussions and negotiations will take place between PA-1 and Pennvest concerning this matter over the next 90-180 days if legislation is passed in Pennsylvania.  No proposals are currently under consideration to resolve this matter.  It is not possible at this date to predict the outcome of such negotiations, but the Company believes that it remains possible that negotiations will lead to a commercially reasonable loan modification agreement  be reached between PA-1 and Pennvest. Subject to the results of the negotiations with Pennvest and pending development of a more robust market for nutrient reductions in Pennsylvania, PA-1 and Bion anticipate that it will be necessary for the Company to evaluate various options with regard to Kreider 1 over the coming months.  Litigation has not commenced in this matter but has been threatened by Pennvest.

The Company currently is not involved in any other material litigation.

Item 1A.  Risk Factors.

Not applicable.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended March 31, 2019 the Company sold the following restricted securities: a) 4,324 shares issued pursuant to our 2006 Consolidated Incentive Plan (‘Plan’), valued at $2,952 in aggregate, to an employee for services, and b) 40,000 shares issued to entities for services, valued at $28,400.  During the quarter ended March 31, 2019, the Company sold 630,000 units at $0.50 per unit consisting of one share of the Company’s restricted common stock and one warrant to purchase half a share of the Company’s restricted common stock at $0.75 until December 31, 2020 and received gross proceeds of $315,000 and net proceeds of $306,000.  In all of these transactions the Company relied on the exemptions in Section 4(2) of the Securities Act of 1933, as amended, and/or under Rule 506 of Regulation D under the Securities Act of 1933, as amended. See Notes to Financial Statements (included herein) for additional details.

The proceeds were utilized for general corporate purposes.

Item 3.  Defaults Upon Senior Securities.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

Not applicable.

Item 6.  Exhibits.

(a)  Exhibits required by Item 601 of Regulation S-K.

Exhibit	Description
31.1	Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) - Filed herewith electronically
31.2	Certification of Executive Chairman, President and CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) - Filed herewith electronically
32.1	Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically
32.2	Certification of Executive Chairman, President and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically
101	XBRL Exhibits

37

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		BION ENVIRONMENTAL TECHNOLOGIES, INC.
Date: May 8, 2019	By:	/s/ Mark A. Smith
		Mark A. Smith, President and Chief Financial Officer (Principal Financial and Accounting Officer)
Date:  May 8, 2019	By:	/s/ Dominic Bassani
		Dominic Bassani, Chief Executive Officer

38

EX-31.1

Exhibit 31.1

SECTION 302 CERTIFICATION

I, Dominic Bassani, certify that:

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 8, 2019	/s/ Dominic Bassani
	Dominic Bassani Chief Executive Officer

EX-31.2

Exhibit 31.2

SECTION 302 CERTIFICATION

I, Mark A. Smith, certify that:

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 8, 2019	/s/ Mark A. Smith
	Mark A. Smith Executive Chairman, President and Interim Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION OF CEO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Dominic Bassani, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 8, 2019	/s/ Dominic Bassani
	Dominic Bassani Chief Executive Officer

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION OF CFO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Interim Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  May 8, 2019	/s/ Mark A. Smith
	Mark A. Smith Executive Chairman, President and Interim Chief Financial Officer

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2019	May 01, 2019
Document Information [Line Items]
Entity Registrant Name	BION ENVIRONMENTAL TECHNOLOGIES INC
Entity Central Index Key	0000875729
Trading Symbol	bnet
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		27,189,120
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Current assets:
Cash	$ 149,169	$ 22,013
Prepaid expenses	4,164	7,474
Deposits and other receivables	1,000	1,000
Total current assets	154,333	30,487
Property and equipment, net (Note 3)	2,964	1,448
Total assets	157,297	31,935
Current liabilities:
Accounts payable and accrued expenses	672,507	719,633
Deferred compensation (Note 4)	844,122	421,641
Loan payable and accrued interest (Note 5)	9,228,213	9,028,983
Total current liabilities	10,777,742	10,201,657
Convertible notes payable - affiliates (Note 6)	3,619,099	3,525,216
Total liabilities	14,396,841	13,726,873
Deficit:
Common stock, no par value, 100,000,000 shares authorized, 27,795,695 and 25,939,892 shares issued, respectively; 27,091,386 and 25,235,583 shares outstanding, respectively
Additional paid-in capital	109,853,840	108,117,330
Subscription receivable - affiliates (Note 7)	(504,650)	(174,650)
Accumulated deficit	(123,638,875)	(121,691,956)
Total Bion’s stockholders’ deficit	(14,289,685)	(13,749,276)
Noncontrolling interest	50,141	54,338
Total deficit	(14,239,544)	(13,694,938)
Total liabilities and deficit	157,297	31,935
Series B Preferred Stock [Member]
Current liabilities:
Series B Redeemable Convertible Preferred stock, $0.01 par value, 50,000 shares authorized; 200 shares issued and outstanding, liquidation preference of $35,500 and $34,000, respectively (Note 7)	32,900	31,400
Series A Preferred Stock [Member]
Deficit:
Preferred stock
Series C Preferred Stock [Member]
Deficit:
Preferred stock

XML

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	100,000,000	100,000,000
Common stock, issued (in shares)	27,795,695	25,939,892
Common stock, outstanding (in shares)	27,091,386	25,235,583
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	50,000	50,000
Preferred stock, issued (in shares)	200	200
Preferred stock, outstanding (in shares)	200	200
Preferred stock, liquidation	$ 35,500	$ 34,000
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	50,000	50,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Series C Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	60,000	60,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

XML

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	305,137	956,826	1,272,626	2,077,519
Depreciation	271	436	966	1,308
Research and development (including stock-based compensation (Note 7))	103,529	680,436	387,442	1,125,937
Total operating expenses	408,937	1,637,698	1,661,034	3,204,764
Loss from operations	(408,937)	(1,637,698)	(1,661,034)	(3,204,764)
Other expense (income):
Gain on extinguishment of liabilities				(718,580)
Conversion inducement		8,000		8,000
Interest expense	100,282	84,714	290,082	276,815
Total other expense (income)	100,282	92,714	290,082	(433,765)
Net loss	(509,219)	(1,730,412)	(1,951,116)	(2,770,999)
Net loss attributable to the noncontrolling interest	505	1,472	4,197	2,486
Net loss applicable to Bion's common stockholders	$ (508,714)	$ (1,728,940)	$ (1,946,919)	$ (2,768,513)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.01)	$ (0.07)	$ (0.07)	$ (0.11)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	26,842,776	24,465,814	26,291,097	24,253,807

XML

Consolidated Statements of Changes in Equity (Deficit) (Unaudited) - 9 months ended Mar. 31, 2019 - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscriptions Receivable [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balances (in shares) at Jun. 30, 2018			25,939,892
Balances at Jun. 30, 2018				$ 108,117,330	$ (174,650)	$ (121,691,956)	$ 54,338	$ (13,694,938)
Issuance of common stock for services (in shares)			70,042
Issuance of common stock for services				45,256				45,256
Vesting of options for services				123,250				123,250
Modification of options				222,300				222,300
Sale of units (in shares)			1,584,733
Sale of units				792,365				$ 792,365
Commissions on sale of units (in shares)			1,028					1,028
Commissions on sale of units				(53,437)				$ (53,437)
Modification of warrants				170,526				170,526
Issuance of warrants				336,250	(330,000)			6,250
Conversion of debt and liabilities (in shares)			200,000
Conversion of debt and liabilities				100,000				100,000
Net loss						(1,946,919)	(4,197)	(1,951,116)
Balances (in shares) at Mar. 31, 2019			27,795,695
Balances at Mar. 31, 2019				$ 109,853,840	$ (504,650)	$ (123,638,875)	$ 50,141	$ (14,239,544)

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,951,116)	$ (2,770,999)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	966	1,308
Accrued interest on loan payable, deferred compensation and other	308,957	303,189
Stock-based compensation	567,582	2,101,160
Gain on extinguishment of liabilities		(718,580)
Conversion inducement		8,000
Decrease in prepaid expenses	3,310	2,321
(Decrease) increase in accounts payable and accrued expenses	(34,189)	80,749
Increase in deferred compensation	495,200	610,200
Net cash used in operating activities	(609,290)	(382,652)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(2,482)
Net cash used in investing activities	(2,482)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of units	792,365	306,997
Commissions on sale of units	(53,437)	(14,875)
Proceeds from exercise of warrants		40,001
Repayment of loans payable - affiliates		(12,500)
Proceeds from loans payable - affiliates		30,500
Net cash provided by financing activities	738,928	350,123
Net increase (decrease) in cash	127,156	(32,529)
Cash at beginning of period	22,013	72,932
Cash at end of period	149,169	40,403
Supplemental disclosure of cash flow information:
Cash paid for interest
Non-cash investing and financing transactions:
Purchase of warrants for subscription receivable - affiliates	330,000	134,650
Conversion of debt and liabilities	100,000
Shares issued for warrant exercise commissions	514
Warrants issued for unit commissions	4,850
Forgiveness of deferred compensation - related parties		$ 1,685,252

XML

Note 1 - Organization, Nature of Business, Going Concern and Management's Plans

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.

     ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

Organization and nature of business:

Bion Environmental Technologies, Inc. (“Bion” or “We” or the “Company”) was incorporated in

1987

in the State of Colorado and has developed and continues to develop patented and proprietary technology and business models that provide comprehensive environmental solutions to a significant source of pollution in United States agriculture, large scale livestock facilities known as Concentrated Animal Feeding Operations (“CAFO’s”). Application of our technology and technology platform can simultaneously remediate environmental problems and improve operational/resource efficiencies by recovering value from the CAFOs’ waste stream that has traditionally been wasted or underutilized, including renewable energy, nutrients (nitrogen and phosphorus)--- in organic and conventional form-- and clean water. Bion’s technologies (and applications related thereto) produce substantial reductions of nutrient releases (primarily nitrogen and phosphorus) to both water and air (including ammonia, which is subsequently re-deposited to the ground) from livestock waste streams based upon our operations and research to date (and

third

party peer review thereof). Our technology simultaneously enables the documentation of the remediation efforts thereby providing the basis for product branding which addresses consumer concerns regarding sustainability and food safety. We are continually involved in research and development to upgrade and improve our technology and technology applications, including integration with

third

party technology. Bion provides comprehensive and cost-effective treatment of livestock waste onsite (and/or at nearby locations), while it is still concentrated and before it contaminates air, soil, groundwater aquifers and/or downstream waters, and, in certain configurations, can be optimized to maximize recovery of marketable nutrients for potential use as fertilizer (organic and/or inorganic) and/or feed additives plus renewable energy (and related environmental credits).

From

2014

through the current

2019

fiscal year, the Company has focused its research and development on augmenting the basic ‘separate and aggregate’ approach of its technology platform to provide additional flexibility and to increase recovery of marketable nutrient by-products (in organic and non-organic forms) and renewable energy production (either/both biogas and/or renewable electricity), thereby increasing potential related revenue streams and reducing dependence of its future projects on the monetization of nutrient reductions (which still remain an important part of project revenue streams). Bion has worked on development of its

third

generation technology (

“3G

Tech”) which is designed to: a) generate significantly greater value from the nutrients and renewable energy recovered from the waste stream, b) treat dry (poultry) waste streams as well as wet waste streams (dairy/beef cattle/swine) while c) maintaining or improving environmental performance. This research and development effort also involves ongoing review of potential “add-ons” and applications to our technology platform for use in different regulatory and/or climate environments. These research and development activities have targeted completion of development of the next generation of Bion’s technology and technology platform. We believe such activities will continue at least through the

2019

calendar year (and likely longer), subject to availability of adequate financing for the Company’s operations, of which there is

no

assurance. Such activities

may

include design and construction of an initial, commercial-scale module utilizing our

3G

Tech to assist in optimization efforts before construction of the full Kreider

2

project (see below) and other Projects.

For the past decade, Bion has been directed toward creating applications of our patented and proprietary waste management technologies and technology platform to pursue JVs in

three

main business opportunities:

1 ) Installation of Bion systems to retrofit and environmentally remediate existing large CAFOs (“Retrofits” and “Retrofit Projects”) in selected markets where:

a) government policy supports such efforts (such as the Chesapeake Bay watershed, Great Lakes Basin states, and/or other states and watersheds facing EPA ‘total maximum daily load’ (“TMDL”) issues), and/or

b) CAFO’s need our technology to obtain permits to expand or develop without negative environmental consequences.

2 ) Development of new state-of-the-art large scale waste treatment facilities (now utilizing the Company’s 3G Tech) which may be developed in conjunction with new CAFOs in strategic locations that were previously impracticable due to environmental impacts or to treat the waste streams from one or more existing large livestock facilities (“Projects”). Some of these Projects may be either a) Integrated Projects as described below, b) ‘central processing facilities’ which receive the waste from multiple livestock facilities, c) Retrofit Projects or d) hybrids with elements of each of these types. Each version will be able to realize revenue from multiple revenue streams potentially generated by our 3G Tech.

3

) Licensing and/or joint venturing of Bion’s technology and applications (primarily) outside North America.

In both categories

1

) and

2

) above, the Company intends to directly participate (whether by joint venture agreement or other contractual arrangements) in the revenues of the Retrofits and Projects.

The opportunities described at

1

) and

2

) above each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion’s efforts are focused on such political and regulatory matters. Bion currently intends to pursue the international opportunities primarily through the use of consultants with existing relationships in target countries.

At this time, our primary focus is on category

2

) above using our

3G

Tech to develop new (or expanded) large-scale Projects with strategic partners (including the Kreider

2

Project) on a joint venture (or other participating contractual form) basis. Bion’s business model opens up the opportunity for JV’s in various forms based upon the revenue generated by our

3G

Tech platform from nutrient reductions, fertilizer co-products and renewable natural gas (which revenue streams will be secured through long term take-off agreements for each of these co-products) providing initial support for financing of required capital expenditures (whether equity or debt). We anticipate that these revenue streams will be supplemented by revenue realized from long-term premium pricing resulting from the sustainable branding opportunity. We believe that the branding opportunity

may

provide the single largest contribution to the economic opportunity over time.

During

2008

the Company commenced actively pursuing the opportunity presented by environmental retrofit and remediation of the waste streams of existing CAFOs which effort has met with very limited success to date. The

first

commercial activity in this area is represented by our agreement with Kreider Farms (“KF”), pursuant to which the Kreider

1

system to treat KF's dairy waste streams to reduce nutrient releases to the environment while generating marketable nutrient credits and renewable energy was designed, constructed and entered full-scale operation during

2011.

On

January 26, 2009

the Board of the Pennsylvania Infrastructure Investment Authority (“Pennvest”) approved a

$7.75

million loan to Bion PA

1,

LLC (

“PA1”

), a wholly-owned subsidiary of the Company, for the initial Kreider Farms project (“Kreider

1

System”). After substantial unanticipated delays, on

August 12, 2010

PA1

received a permit for construction of the Kreider

1

System. Construction activities commenced during

November 2010.

The closing/settlement of the Pennvest Loan took place on

November 3, 2010.

PA1

finished the construction of the Kreider

1

System and entered a period of system ‘operational shakedown’ during

May 2011.

The Kreider

1

System reached full, stabilized operation by the end of the

2012

fiscal year. During

2011

the Pennsylvania Department of Environmental Protection (“PADEP”) re-certified the nutrient credits for this project. The PADEP issued final permits for the Kreider

1

System (including the credit verification plan) on

August 1, 2012

on which date the Company deemed that the Kreider

1

System was ‘placed in service’. As a result,

PA1

commenced generating nutrient reduction credits for potential sale while continuing to utilize the Kreider

1

System to test improvements and add-ons. However, to date liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth, which limited liquidity/depth has negatively impacted Bion’s business plans and has resulted in challenges to monetizing the nutrient reductions created by

PA1’s

existing Kreider

1

System and Bion’s other proposed projects. These difficulties have prevented

PA1

from generating any material revenues from the Kreider

1

System to date and raise significant questions as to when, if ever,

PA1

will be able to generate such revenues fromthe Kreider

1

System.

PA1

has had sporadic discussions/negotiations with Pennvest related to forbearance and/or re-structuring its obligations pursuant to the Pennvest Loan for more than

four

years. In the context of such discussions/negotiations,

PA1

elected

not

to make interest payments to Pennvest on the Pennvest Loan since

January 2013.

Additionally, the Company has

not

made any principal payments, which were to begin in fiscal

2013,

and, therefore, the Company has classified the Pennvest Loan as a current liability as of

March 31, 2019.

Due to the failure of the Pennsylvania nutrient reduction credit market to develop, the Company determined (on

three

separate occasions) that the carrying amount of the property and equipment related to the Kreider

1

System exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits. Therefore,

PA1

and the Company recorded impairments related to the value of the Kreider

1

assets totaling

$3,750,000

through

June 30, 2015.

During the

2016

fiscal year,

PA1

and the Company recorded an additional impairment of

$1,684,562

to the value of the Kreider

1

assets which reduced the value on the Company’s books to zero. This impairment reflects management’s judgment that the salvage value of the Kreider

1

assets roughly equals

PA1’s

contractual obligations related to the Kreider

1

System, including expenses related to decommissioning of the Kreider

1

System, costs associated with needed capital upgrade expenses, and re-certification/ permitting amendments.

On

September 25, 2014,

Pennvest exercised its right to declare the Pennvest Loan in default and accelerated the Pennvest Loan and demanded that

PA1

pay

$8,137,117

(principal, interest plus late charges) on or before

October 24, 2014.

PA1

did

not

make the payment and does

not

have the resources to make the payments demanded by Pennvest.

PA1

has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected

PA1’s

proposal made during the fall of

2014.

No

formal proposals are presently under consideration and only sporadic communication has taken place regarding the matters involved over the last

48

months. It is

not

possible at this date to predict the outcome of such this matter, but the Company believes that a loan modification agreement (coupled with an agreement regarding an update and re-start of full operations of the Kreider

1

System)

may

be reached in the future if/when a more robust market for nutrient reductions develops in Pennsylvania, of which there is

no

assurance.

PA1

and Bion will continue to evaluate various options with regard to Kreider

1

over the next

30

-

180

days.

During

August 2012,

the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider

1

System met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been (and is now) solely an obligation of

PA1

since that date.

The economics (potential revenues, profitability and continued operation) of the Kreider

1

System are based almost entirely on the long term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up.

On

May 5, 2016,

Bion

PA2

LLC (

“PA2”

) executed a stand-alone joint venture agreement with Kreider Farms covering matters related to development and operation of a system to treat the waste streams from Kreider’s poultry facilities (“Kreider

2”

).

The Kreider projects are owned and operated by Bion through separate subsidiaries, in which Kreider has the option to acquire a noncontrolling interest. Substantial capital (equity and/or debt) has been and will continue to be expended on these projects. Additional funds will be required for continuing operations and additional capital expenditures for upgrades at Kreider

1

until sufficient revenues can be generated, of which there is

no

assurance. The Company anticipates that the Kreider

1

System will generate revenue primarily from the sale of nutrient reduction (and/or other) environmental credits. A portion of Bion’s research and development activities has taken place at the Kreider

1

facility.

Kreider Farms –

3G

Tech Project

Bion is completing an envelope of policy change and technology pilots that will allow it to move forward with the

first

commercial large scale

3G

Tech project at Kreider Farms. Having recently received a Notice of Allowance of the initial

3G

Tech patent (and subsequent filing of related additional patent applications/continuations), Bion is focused on

two

key tasks during the remainder of the

2019

fiscal and calendar year that will ‘complete the envelope’ and allow Bion to launch active development of the Kreider

2

poultry project (and/or other Projects) in

2019:

1.

Support for adoption of PA SB

575

(successor to SB

799

): This will create a competitively-bid market for nutrient reductions/Credits that we believe will provide support for project financing for Kreider

2

prior to development of markets for the coproducts from Kreider

2

are established.

2.

Installation of a small-scale

3G

Tech ammonia recovery system to produce ammonium bicarbonate to be used for grower trials and to make application to OMRI for organic certification.

The

3G

Tech Kreider

2

Project is planned for

two

(or more) locations. It is intended to treat the waste from Kreider’s

1,800

dairy cows and approximately

six million

egg layer chickens (with capacity for an additional

three million

layers). The Kreider

2

Project will be designed with modules with capacity of

450

tons (or more) per day of waste and will remove nitrogen and phosphorus from the waste stream that will be converted into high-value coproducts instead of polluting local and downstream waters. The Kreider

2

Project is planned to be built in

three

phases and

may

be expanded to include a ‘central processing facility’ with modules that will accept transported waste from the region on fee basis.

Bion has a long-standing relationship with Kreider Farms including a

2016

joint venture agreement related to this facility. Kreider has already made a significant investment in upgrading its poultry facilities to maximize the treatment and recovery efficiencies that can be achieved with Bion’s technology. We are cautiously optimistic that once PA

SB575

(the recently introduced successor to

SB799

) will be passed during the current fiscal year and that once passed, a market will be put in place for long-term commercial sale of the nutrient reduction credits produced at Kreider

2.

Bion anticipates that it

may

require up to

6

months after

SB575

becomes law to develop the rules/regulations related to the competitive bidding program. If the competitive bidding program is implemented, we intend to arrange project financing for the Kreider

2

Project during

2019.

Assuming there are positive developments related to the market for nutrient reductions in Pennsylvania, the Company intends to pursue development, design and construction of the Kreider

2

poultry waste/renewable energy project with a goal of achieving operational status for its initial modules during

2020.

However, as discussed above, this Project faces challenges related to the current limits of the existing nutrient reduction market and funding of technology-based, verifiable agricultural nutrient reductions which are anticipated to constitute the largest share of its revenues.

Bion’s current long-term goal is to acquire or develop, or have in a development pipeline,

6

to

12

Projects over the next

36

to

48

months.

A significant portion of Bion’s activities concern efforts with private and public stakeholders (at local and state level) in Pennsylvania (and other Chesapeake Bay and Midwest and Great Lakes states) and at the federal level EPA and the Department of Agriculture (“USDA”) (and other executive departments) and Congress) to establish appropriate public policies which will create regulations and funding mechanisms that foster installation of the low cost environmental solutions that Bion (and others) can provide through clean-up of agricultural waste streams. The Company anticipates that such efforts will continue in Pennsylvania and other Chesapeake Bay watershed states throughout the next

12

months and in various additional states thereafter.

Going concern and management’s plans:

The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has

not

generated significant revenues and has incurred net losses (including significant non-cash expenses) of approximately

$3,018,000

and

$2,463,000

during the years ended

June 30, 2018

and

2017,

respectively, and a net loss of approximately

$1,951,000

during the

nine

months ended

March 31, 2019.

At

March 31, 2019,

the Company has a working capital deficit and a stockholders’ deficit of approximately

$10,623,000

and

$14,290,000,

respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do

not

include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that

may

result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is

not

currently generating any significant revenues.

During the years ended

June 30, 2018

and

2017,

the Company received total proceeds of approximately

$418,000

and

$452,000

from the sale of its debt and equity securities. Proceeds during the

2018

and

2017

fiscal years have been lower than in earlier years which reduction has negatively impacted the Company’s business development efforts.

During the

nine

months ended

March 31, 2019,

the Company received gross proceeds of approximately

$792,000

from the sale of its equity securities and paid approximately

$53,000

in commissions.

During fiscal years

2018

and

2017,

the Company continued to experience greater difficulty in raising equity funding than in the prior years. As a result, the Company faced, and continues to face, significant cash flow management challenges due to working capital constraints. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes

4

and

6

) and members of the Company’s senior management have made loans to the Company. During the year ended

June 30, 2018,

senior management and certain core employees and consultants agreed to a

one

-time extinguishment of liabilities owed by the Company which in aggregate totaled

$2,404,000.

Additionally, the Company made reductions in its personnel during the years ended

June 30, 2014

and

2015

and again during the year ended

June 30, 2018.

The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company does

not

have greater success in its efforts to raise needed funds during the remainder of the current fiscal year (and subsequent periods), management will need to consider deeper cuts (including additional personnel cuts) and curtailment of operations (including possibly Kreider

1

operations) and/or research and development activities.

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including Integrated Projects and the Kreider

2

facility) and CAFO Retrofit waste remediation systems and to continue to operate the Kreider

1

facility. The Company anticipates that it will seek to raise from

$2,500,000

to

$50,000,000

or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) during the next

twelve

months. However, as discussed above, there is

no

assurance, especially in light of the difficulties the Company has experienced in recent periods and the extremely unsettled capital markets that presently exist (especially for companies like us), that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

There is

no

realistic likelihood that funds required during the next

twelve

months (or in the periods immediately thereafter) for the Company’s basic operations and/or proposed Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be

no

assurance that any such required funds, if available, will be available on attractive terms or that they will

not

have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

XML

Note 2 - Significant Accounting Policies

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

2.

     SIGNIFICANT ACCOUNTING POLICIES

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services,

PA1,

and

PA2;

and its

58.9%

owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at

March 31, 2019,

and the results of operations and cash flows of the Company for the

three

and

nine

months ended

March 31, 2019

and

2018.

Operating results for the

three

and

nine

months ended

March 31, 2019

are

not

necessarily indicative of the results that

may

be expected for the year ending

June 30, 2019.

Cash and cash equivalents:

The Company considers all highly liquid investments purchased with an original maturity of

three

months or less to be cash and cash equivalents.

Property and equipment:

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally

three

to

twenty

years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in

no

related asset being recognized in the Company’s balance sheet) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have

no

direct relationship to the value of the Company’s patents. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset

may

not

be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

Stock-based compensation:

The Company follows the provisions of Accounting Standards Codification (“ASC”)

718,

which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

Derivative Financial Instruments:

Pursuant to ASC Topic

815

“Derivatives and Hedging” (“Topic

815”

), the Company reviews all financial instruments for the existence of features which

may

require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

Warrants:

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

Concentrations of credit risk:

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times

may

exceed federally insured limits. The Company has

not

experienced any losses on such accounts.

Noncontrolling interests:

In accordance with ASC

810,

“Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

Fair value measurements:

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has

three

levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

Level

1

– quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level

2

– observable inputs other than Level

1,

quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are

not

active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

Level

3

– assets and liabilities whose significant value drivers are unobservable.

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability

may

fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are

not

practicable to estimate due to the related party nature of the underlying transactions.

Revenue Recognition:

The Company currently does

not

generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”)

606

“Revenue from Contracts with Customers”.

Loss per share:

Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the

three

and

nine

months ended

March 31, 2019

and

2018,

the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:

	March 31, 2019		March 31, 2018
Warrants		16,591,570		12,176,269
Options		7,106,600		6,827,225
Convertible debt		8,449,932		7,337,805
Convertible preferred stock		17,750		16,750

The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the

three

and

nine

months ended

March 31, 2019

and

2018:

	Three months ended March 31, 2019			Three months ended March 31, 2018			Nine months ended March 31, 2019			Nine months ended March 31, 2018
Shares issued – beginning of period		27,121,371			25,011,939			25,939,892			24,748,213
Shares held by subsidiaries (Note 7)		(704,309	)		(704,309	)		(704,309	)		(704,309	)
Shares outstanding – beginning of period		26,417,062			24,307,630			25,235,583			24,043,904
Weighted average shares issued during the period		425,714			158,184			1,055,514			209,903
Diluted weighted average shares – end of period		26,842,776			24,465,814			26,291,097			24,253,807

Use of estimates:

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements:

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

In

May 2017,

the FASB issued ASU

No.

2017

-

09

“Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment awards must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU

No.

2017

-

09

will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods beginning after

December 15, 2017,

with early adoption permitted. The adoption of ASU

2017

-

09

did

not

have a material impact on the Company’s financial statements.

XML

Note 3 - Property and Equipment

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

3.

     PROPERTY AND EQUIPMENT:

Property and equipment consists of the following:

	March 31, 2019			June 30, 2018
Machinery and equipment	$	2,222,670		$	2,222,670
Buildings and structures		401,470			401,470
Computers and office equipment		173,245			171,613
		2,797,385			2,795,753
Less accumulated depreciation		(2,794,421	)		(2,794,305	)
	$	2,964		$	1,448

Management reviewed property and equipment for impairment as of

June 30, 2016

and determined that the carrying amount of property and equipment related to the Kreider

1

project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits and potentially needed capital expenditures and it was also determined that the salvage value of the system components will be offset by contractual decommissioning obligations. Kreider

1

was measured at estimated fair value on a non-recurring basis using level

3

inputs, which resulted in an impairment of

$1,684,562

of the property and equipment for the year ended

June 30, 2016.

As of

June 30, 2016,

the net book value of Kreider

1

was

zero

. As of

March 31, 2019,

management believes that

no

additional impairment exists.

Depreciation expense was

$271

and

$436

for the

three

months ended

March 31, 2019

and

2018,

respectively and

$966

and

$1,308

for the

nine

months ended

March 31, 2019

and

2018,

respectively.

XML

Note 4 - Deferred Compensation

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

4.

     DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling

$844,122

and

$345,929

as of

March 31, 2019

and

2018,

respectively. Included in the deferred compensation balances as of

March 31, 2019,

are

$447,019

and

$79,016

owed Dominic Bassani (“Bassani”), the Company’s Chief Executive Officer and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective

January 1, 2015,

whereby unpaid compensation earned after

January 1, 2015,

accrues interest at

4%

per annum and can be converted into shares of the Company’s common stock at the election of the employee during the

first

five

calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last

10

trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of

March 31, 2018

was

$124,612

and

$72,355,

respectively. The Company also owes various consultants, pursuant to various agreements, for deferred compensation of

$244,603

and

$75,478

as of

March 31, 2019

and

2018,

respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at

3%

per annum. Bassani and Smith have each been granted the right to convert up to

$300,000

of deferred compensation balances at a price of

$0.75

per share until

December 31, 2019 (

to be issued pursuant to the

2006

Plan). Smith has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the

2006

Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is

no

current) private placement. The Company also owes a current employee deferred compensation of

$984

which is convertible into

1,348

shares of the Company’s common stock as of

March 31, 2019

and, a former employee

$72,500,

which is

not

convertible and is non-interest bearing.

During the

nine

months ended

March 31, 2019,

Smith elected to convert deferred compensation and accounts payable of

$87,063

and

$12,937,

respectively, into an aggregate

200,000

units at

$0.50

per unit, with each unit consisting of

one

share of the Company’s restricted common stock and

one

warrant to purchase

one

half of a share of the Company’s restricted common stock for

$0.75

per share until

December 31, 2022.

The Company recorded interest expense of

$14,344

(

$11,048

with related parties) and

$32,299

(

$26,084

with related parties) for the

nine

months ended

March 31, 2019

and

2018,

respectively.

XML

Note 5 - Loan Payable

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Debt Disclosure [Text Block]

5.

     LOAN PAYABLE:

PA1,

the Company’s wholly-owned subsidiary, owes

$9,228,213

as of

March 31, 2019

under the terms of the Pennvest Loan related to the construction of the Kreider

1

System including accrued interest and late charges totaling

$1,474,213

as of

March 31, 2019.

The terms of the Pennvest Loan provided for funding of up to

$7,754,000

which was to be repaid by interest-only payments for

three

years, followed by an additional

ten

-year amortization of principal. The Pennvest Loan accrues interest at

2.547%

per annum for years

1

through

5

and

3.184%

per annum for years

6

through maturity. The Pennvest Loan required minimum annual principal payments of approximately

$3,502,000

in fiscal years

2013

through

2018,

and

$771,000

in fiscal year

2019,

$794,000

in fiscal year

2020,

$819,000

in fiscal year

2021,

$846,000

in fiscal year

2022,

$873,000

in fiscal year

2023

and

$149,000

thereafter. The Pennvest Loan is collateralized by the Kreider

1

System and by a pledge of all revenues generated from Kreider

1

including, but

not

limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest is entitled to participate in the profits from Kreider

1

calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of

$59,109

and

$49,373

for the

three

months ended

March 31, 2019

and

2018,

respectively. The Company has incurred interest expense related to the Pennvest Loan of

$172,856

and

$148,121

for the

nine

months ended

March 31, 2019

and

March 31, 2018,

respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market to date,

PA1

commenced negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan. In the context of such negotiations,

PA1

has elected

not

to make interest payments to Pennvest on the Pennvest Loan since

January 2013.

Additionally, the Company has

not

made any principal payments, which were to begin in fiscal

2013,

and, therefore, the Company has classified the Pennvest Loan as a current liability as of

March 31, 2019.

On

September 25, 2014,

Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and demanded that

PA1

pay

$8,137,117

(principal, interest plus late charges) on or before

October 24, 2014.

PA1

did

not

make the payment and does

not

have the resources to make the payment demanded by Pennvest.

PA1

has engaged in on/off discussions and negotiations with Pennvest concerning this matter but

no

such discussions/negotiations are currently active. As of the date of this report,

no

formal proposals are presently under consideration and only sporadic communication has taken place regarding the matters involved over the past

48

months. It is

not

possible at this date to predict the outcome of this matter, but the Company believes it is possible that an agreement

may

yet be reached that will result in a viable loan modification. Subject to the results of the negotiations with Pennvest and pending development of a more robust market for nutrient reductions in Pennsylvania,

PA1

and Bion will continue to evaluate various options with regard to Kreider

1

over the next

30

-

180

days.

In connection with the Pennvest Loan financing documents, the Company provided a ‘technology guaranty’ regarding nutrient reduction performance of Kreider

1

which was structured to expire when Kreider

1’s

nutrient reduction performance had been demonstrated. During

August 2012

the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider

1

System had surpassed the requisite performance criteria and that the Company’s ‘technology guaranty’ was met. As a result, the Pennvest Loan is solely an obligation of

PA1.

XML

Note 6 - Convertible Notes Payable - Affiliates

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Convertible Debt [Text Block]

6.

     CONVERTIBLE NOTES PAYABLE - AFFILIATES:

January 2015

Convertible Notes

The

January 2015

Convertible Notes accrue interest at

4%

per annum and were due and payable on

December 31, 2017.

Effective

June 30, 2017,

the maturity dates were extended on the

January 2015

Convertible Notes until

July 1, 2019

and were further extended to

July 1, 2021

effective

September 30, 2018.

The

January 2015

Convertible Notes (including accrued interest, plus all future deferred compensation), are convertible, at the sole election of the noteholder, into Units consisting of

one

share of the Company’s common stock and

one

half warrant to purchase a share of the Company’s common stock, at a price of

$0.50

per Unit until

December 31, 2020.

The warrant contained in the Unit shall be exercisable at

$1.00

per share until

December 31, 2020.

The original conversion price of

$0.50

per Unit approximated the fair value of the Units at the date of the agreements; therefore

no

beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC

815

-

15

“Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are

not

“clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was

not

required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is

not

readily convertible to cash in accordance with ASC

815

-

10,

“Derivatives and Hedging”.

As of

March 31, 2019,

the

January 2015

Convertible Note balances, including accrued interest, owed Bassani, Smith and Edward Schafer (“Schafer”), the Company’s Vice Chairman, were

$1,713,318,

$889,703

and

$442,547,

respectively. As of

March 31, 2018,

the

January 2015

Convertible Note balances, including accrued interest, owed Bassani, Smith and Schafer were

$1,654,736,

$859,282

and

$427,416,

respectively. The Company recorded interest expense related to the

January 2015

Convertible Notes of

$25,677

for both of the

three

months ended

March 31, 2019

and

2018,

respectively. The Company recorded interest expense of

$78,172

for both the

nine

months ended

March 31, 2019

and

2018,

respectively.

During the

nine

months ended

March 31, 2019,

the Company agreed to sell Bassani and Smith,

3,000,000

and

300,000

warrants, respectively, exercisable at

$0.60

per share until

June 30, 2025

and

June 30, 2023,

respectively. The purchase price for the warrants is

$0.10

per warrant and is payable with secured promissory notes of

$300,000

and

$30,000

from Bassani and Smith, respectively, both of which are secured by portions of their

January 2015

Convertible Notes (Note

7

). The promissory notes accrue interest at

4%

per annum and as of

March 31, 2019

the accrued interest owed by Bassani and Smith is

$7,956

and

$796,

respectively.

September 2015

Convertible Notes

During the year ended

June 30, 2016,

the Company entered into

September 2015

Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The initial principal balances of the

September 2015

Convertible Notes were

$405,831,

$16,382

and

$82,921,

respectively. The

September 2015

Convertible Notes bear interest at

4%

per annum, had maturity dates of

December 31, 2017

and

may

be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of

$0.60

per share. As the conversion price of

$0.60

approximated the fair value of the common shares at the date of the

September 2015

Convertible Notes,

no

beneficial conversion feature exists. During the year ended

June 30, 2018,

Bassani and the Company agreed to split his original

September 2015

Convertible Note into

two

replacement notes with all the terms remaining the same. One of the replacement notes’ original principal is

$130,000,

which is being held by the Company as collateral for a subscription receivable promissory note from Bassani. During the

nine

months ended

March 31, 2019,

with the Company’s approval, Bassani sold

$300,000

of his

second

replacement note to a Shareholder with all the terms remaining the same.

The balances of the

September 2015

Convertible Notes as of

March 31, 2019,

including accrued interest owed Bassani, Schafer and Shareholder, are

$158,544,

$18,716

and

$396,271,

respectively. The balances of the

September 2015

Convertible Notes as of

March 31, 2018,

including accrued interest, were

$447,989,

$18,061

and

$91,417,

respectively.

Effective

June 30, 2017,

the maturity dates of the

September 2015

Convertible Notes due Bassani and Schafer were extended until

July 1, 2019

and during the year ended

June 30, 2018,

the maturity date of the note due a Shareholder was extended until

July 1, 2019.

During the

nine

months ended

March 31, 2019,

the maturity dates of the all the

September 2015

Convertible Notes were extended until

July 1, 2021.

The Company recorded interest expense of

$5,293

and

$5,341

for the

three

months ended

March 31, 2019

and

2018,

respectively. The Company recorded interest expense of

$15,712

and

$15,743

for the

nine

months ended

March 31, 2019

and

2018,

respectively.

XML

Note 7 - Stockholders' Equity

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

7.

     STOCKHOLDERS' EQUITY:

Series B Preferred stock:

At

July 1, 2014,

the Company had

200

shares of Series B redeemable convertible Preferred stock outstanding with a par value of

$0.01

per share, convertible at the option of the holder at

$2.00

per share, with dividends accrued and payable at

2.5%

per quarter. The Series B Preferred stock is mandatorily redeemable at

$100

per share by the Company

three

years after issuance and accordingly was classified as a liability. The

200

shares have reached their maturity date, but due to the cash constraints of the Company have

not

been redeemed.

During the years ended

June 30, 2018

and

2017,

the Company declared dividends of

$2,000

and

$2,000

respectively. During the

nine

months ended

March 31, 2019,

the Company declared dividends of

$1,500.

At

March 31, 2019,

accrued dividends payable are

$15,500.

The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements.

Common stock:

Holders of common stock are entitled to

one

vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has

no

preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and

may

be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company

may

designate in the future.

Centerpoint holds

704,309

shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

During the

nine

months ended

March 31, 2019,

the Company issued

70,042

shares of the Company’s common stock at prices ranging from

$0.50

to

$0.74

per share for services valued at

$45,256,

in the aggregate, to a consultant and an employee.

During the

nine

months ended

March 31, 2019,

the Company issued

1,028

shares as commissions for the warrant exercises during the year ended

June 30, 2018

valued at

$514.

During the

nine

months ended

March 31, 2019,

the Company entered into subscription agreements under

three

different offerings to sell units for

$0.50

per unit, with each unit consisting of

one

share of the Company’s restricted common stock and

one

warrant to purchase

one

half of a share of the Company’s restricted common stock for

$0.75

per share with expiry dates ranging from

June 30, 2019

through

December 31, 2020,

and pursuant thereto, the Company issued

1,584,733

units for total proceeds of

$792,365,

net proceeds of

$738,928

after commissions. The Company allocated the proceeds from the

1,584,733

shares and the

792,369

warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be

$0.05

per warrant. As a result,

$28,176

was allocated to the warrants and

$764,189

was allocated to the shares, and both were recorded as additional paid in capital.

During the

nine

months ended

March 31, 2019,

Smith elected to convert deferred compensation and accounts payable of

$87,063

and

$12,937,

respectively, into an aggregate

200,000

units at

$0.50

per unit, with each unit consisting of

one

share of the Company’s restricted common stock and

one

warrant to purchase

one

half of a share of the Company’s restricted common stock for

$0.75

per share until

December 31, 2022.

Warrants:

As of

March 31, 2019,

the Company had approximately

16.6

million warrants outstanding, with exercise prices from

$0.60

to

$2.00

and expiring on various dates through

June 30, 2025.

The weighted-average exercise price for the outstanding warrants is

$0.95,

and the weighted-average remaining contractual life as of

March 31, 2019

is

3.8

years.

During the

nine

months ended

March 31, 2019,

warrants to purchase

70,069

shares of common stock of the Company at prices ranging from

$0.85

to

$3.00

per share expired.

During the

nine

months ended

March 31, 2019,

the Company entered into subscription agreements under

three

different offerings to sell units for

$0.50

per unit, with each unit consisting of

one

share of the Company’s restricted common stock and

one

warrant to purchase

one

half of a share of the Company’s restricted common stock for

$0.75

per share with expiry dates ranging from

June 30, 2019

through

December 31, 2020,

and pursuant thereto, the Company issued

1,584,733

units for total proceeds of

$792,365,

net proceeds of

$738,928

after commissions. The Company allocated the proceeds from the

1,584,733

shares and the

792,369

warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be

$0.05

per warrant. As a result,

$28,176

was allocated to the warrants and

$764,189

was allocated to the shares, and both were recorded as additional paid in capital.

During the

nine

months ended

March 31, 2019,

the Company received an interest bearing, secured promissory note for

$300,000

from Bassani as consideration to purchase warrants to purchase

3,000,000

shares of the Company’s restricted common stock, which warrants are exercisable at

$0.60

and have expiry dates of

December 31, 2025.

The promissory note bears interest at

4%

per annum, is secured by Bassani’s

January 2015

Convertible Note and as of

March 31, 2019

the accrued interest was

$7,956.

The secured promissory note is payable

July 1, 2020.

During the

nine

months ended

March 31, 2019,

the Company received an interest bearing, secured promissory note for

$30,000

from Smith as consideration to purchase warrants to purchase

300,000

shares of the Company’s restricted common stock, which warrants are exercisable at

$0.60

and have expiry dates of

December 31, 2023.

The warrants have a

75%

exercise bonus. The promissory note bears interest at

4%

per annum, is secured by Smith’s

2015

January 2015

Convertible Note and as of

March 31, 2019

the accrued interest was

$796.

The secured promissory note is payable on

July 1, 2020.

During the

nine

months ended

March 31, 2019,

Smith elected to convert deferred compensation and accounts payable of

$87,063

and

$12,937,

respectively, into an aggregate

200,000

units at

$0.50

per unit, with each unit consisting of

one

share of the Company’s restricted common stock and

one

warrant to purchase

one

half of a share of the Company’s restricted common stock for

$0.75

per share until

December 31, 2022.

During the

nine

months ended

March 31, 2019,

the Company issued

125,000

warrants to a consultant to purchase

125,000

shares of the Company’s restricted common stock, which warrants have exercise prices ranging between

$0.74

and

$1.20

per share and have expiry dates of ranging from

August 27, 2020

through

October 27, 2020.

The warrants were in exchange for services expensed at

$6,250,

in aggregate.

During the

nine

months ended

March 31, 2019,

the Company agreed to extend the expiration dates of

5,229,188

warrants owned by certain individuals (including

1,765,000

owned by Bassani and

3,104,010

owned by Smith) which were scheduled to expire at various dates ranging from

September 30, 2018

through

December 31, 2021.

The Company recorded non-cash compensation expense related to the modification of the warrants of

$163,026

(

$88,250

and

$68,758

for Bassani and Smith, respectively) and

$7,500

as interest expense.

Stock options:

The Company’s

2006

Consolidated Incentive Plan, as amended (the

“2006

Plan”), provides for the issuance of options (and/or other securities) to purchase up to

30,000,000

shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the

2006

Plan

may

be established at the discretion of the Board of Directors, but

no

option

may

be exercisable for more than

ten

years.

During the

nine

months ended

March 31, 2019,

the Company approved the modification of existing stock options held by Smith, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of

$222,300.

The Company recorded compensation expense related to employee stock options of

$5,250

and

$1,269,700

for the

three

months ended

March 31, 2019

and

2018,

respectively, and

$123,250

and

$1,369,350

for the

nine

months ended

March 31, 2019

and

2018,

respectively. The Company granted

350,000

and

2,647,500

options during the

nine

months ended

March 31, 2019

and

2018,

respectively.

The fair value of the options granted during the

nine

months ended

March 31, 2019

and

2018

were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

	Weighted Average, March 31, 2019		Range, March 31, 2019			Weighted Average, March 31, 2018		Range, March 31, 2018
Volatility		69%	58%	-	76%		74%	68%	-	75%
Dividend yield		-		-			-		-
Risk-free interest rate		2.71%	2.52%	-	2.78%		2.44%	1.75%	-	2.64%
Expected term (years)		3.8	1.9	to	4.3		5	3	-	6

The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

A summary of option activity under the

2006

Plan for the

nine

months ended

March 31, 2019

is as follows:

	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at July 1, 2018		6,827,225		$	1.11		3.8	$	-
Granted		350,000			0.68
Exercised		-			-
Forfeited		-			-
Expired		(70,625	)		1.26
Outstanding at March 31, 2019		7,106,600		$	1.09		3.3	$	57,050
Exercisable at March 31, 2019		7,106,600		$	1.09		3.3	$	57,050

The following table presents information relating to nonvested stock options as of

March 31, 2019:

	Options			Weighted Average Grant-Date Fair Value
Nonvested at July 1, 2018		-		$	-
Granted		350,000			0.35
Vested		(350,000	)		0.35
Nonvested at March 31, 2019		-		$	-

The total fair value of stock options that vested during the

nine

months ended

March, 2019

and

2018

was

$123,250

and

$1,376,250

respectively. As of

March 31, 2019,

the Company had

no

unrecognized compensation cost related to stock options.

Stock-based employee compensation charges in operating expenses in the Company’s financial statements for the

three

and

nine

months ended

March 31, 2019

and

2018

are as follows:

	Three months ended March 31, 2019		Three months ended March 31, 2018		Nine months ended March 31, 2019		Nine months ended March 31, 2018
General and administrative:
Fair value of stock bonuses expensed	$	-	$	1,500	$	-	$	8,723
Change in fair value from modification of option terms		-		-		211,185		243,761
Change in fair value from modification of warrant terms		-		7,091		118,233		163,956
Fair value of stock options expensed		5,250		682,485		97,375		782,135
Total	$	5,250	$	691,076	$	426,793	$	1,198,575
Research and development:
Fair value of stock bonus expensed	$	-	$	-	$	-	$	15,098
Change in fair value from modification of option terms		-		-		11,115		105,895
Change in fair value from modification of warrant terms		-		219		44,793		132,896
Fair value of stock options expensed		-		587,215		25,875		587,215
Total	$	-	$	587,434	$	81,783	$	841,104

XML

Note 8 - Commitments and Contingencies

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

8.

     COMMITMENTS AND CONTINGENCIES:

Employment and consulting agreements:

Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements and terms since

March 2003.

Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since

March 2003.

On

October 10, 2016,

the Company approved a month to month contract extension with Smith which includes provisions for i) a monthly deferred salary of

$18,000

effective

October 1, 2016

until the Board of Directors re-instates cash payments to all employees and consultants who are deferring compensation, ii) the right to convert up to

$125,000

of his deferred compensation, at his sole election, at

$0.75

per share, until

March 15, 2018 (

which was expanded on

April 27, 2017

to the right to convert up to

$300,000

of his deferred compensation, at his sole election, at

$0.75

per share, and subsequently extended until

December 31, 2019),

and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to

third

parties. Smith agreed effective

July 29, 2018

to continue to serve the Company under these terms.

Since

March 31, 2005,

the Company has had various agreements with Brightcap and/or Bassani, through which the services of Bassani are provided (any reference to Brightcap or Bassani for all purposes are the same individual). The Board appointed Bassani as the Company's CEO effective

May 13, 2011.

On

February 10, 2015,

the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to

December 31, 2017, (

with the Company having an option to extend the term an additional

six

months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation (

$31,000

per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation. During

October 2016

Bassani was granted the right to convert up to

$125,000

of his deferred compensation, at his sole election, at

$0.75

per share, until

March 15, 2018 (

which was expanded on

April 27, 2017

to the right to convert up to

$300,000

of his deferred compensation, at his sole election, at

$0.75

per share, and subsequently extended until

December 31, 2019).

During

February 2018,

the Company agreed to the material terms for a binding

two

-year extension agreement for Bassani’s services as CEO, while a detailed, fully executed agreement is still being negotiated and will be finalized in the future. Bassani’s salary will remain

$372,000

per year, which will continue to be accrued until there is adequate cash available while negotiations proceed toward the re-instatement of a least a partial cash payment. Additionally, the Company has agreed to pay him

$2,000

per month to be applied to life insurance premiums. On

August 1, 2018,

in the context of extending his agreement to provide services to the Company on a full time basis through

December 31, 2022)

plus

2

years after that on a part-time basis, the Company received an interest bearing secured promissory note for

$300,000

from Bassani as consideration to purchase warrants to purchase

3,000,000

shares of the Company’s restricted common stock, which warrants are exercisable at

$0.60

and have expiry dates of

June 30, 2025.

The promissory note is secured by Bassani’s

$300,000

of

January 2015

Convertible Note (Notes

6

and

7

) and as of

March 31, 2019

the accrued interest was

$7,956.

Execution/exercise bonuses:

As part of agreements the Company entered into with Bassani and Smith effective

May 15, 2013,

they were each granted the following: a) a

50%

execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to

50%

of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to

five

years (

one

year at a time) by annual payments of

$.05

per option or warrant to the Company on or before a date during the

three

months prior to expiration of the exercise period at least

three

business days before the end of the expiration period. Effective

January 1, 2016

such annual payments to extend warrant exercise periods have been reduced to

$.01

per option or warrant.

During the year ended

June 30, 2014,

the Company extended

50%

execution/exercise bonuses with the same terms as described above to Schafer and to Jon Northrop (“Northrop”), the Company’s other board member.

During the year ended

June 30, 2018,

the Company extended

50%

execution/exercise bonuses with the same terms as described above to all options and warrants issued prior to

November 7, 2017,

to an employee and

two

former employees who are now consultants.

During the year ended

June 30, 2018,

the Company increased the above

50%

execution/exercise bonus on all outstanding options and warrants owned or acquired in the future by Bassani, Smith and Schafer to

75%

(to the extent such existing exercise bonus is less than

75%

).

During the

nine

months ended

March 31, 2019,

the Company approved the right to extend the exercise period of all or part of any options or warrants granted in the past or in the future, for up to

five

years (

one

year at a time) by annual payments of

$0.01

per option/warrant for

one

of its employees.  The extension payment

may

be made in i) cash; ii) by reduction of sums owed by the Company, and iii) by reduction of applicable exercise bonuses.

As of

March 31, 2019,

the execution/exercise bonuses ranging from

50

-

90%

were applicable to

6,934,600

of the Company’s outstanding options and

12,032,095

of the Company’s outstanding warrants.

Litigation:

On

September 25, 2014,

Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and has demanded that

PA1

pay

$8,137,117

(principal, interest plus late charges) on or before

October 24, 2014.

PA1

did

not

make the payment and does

not

have the resources to make the payment demanded by Pennvest. During

August 2012,

the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider

1

system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan is now solely an obligation of

PA1.

No

litigation has commenced related to this matter but such litigation is likely if negotiations do

not

produce a resolution (Notes

1

and Note

5

).

The Company currently is

not

involved in any other material litigation.

XML

Note 9 - Related Party Transactions

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

9.

     RELATED PARTY TRANSACTIONS:

The Coalition for Affordable Bay Solutions (“CABS”), a

not

-for-profit organization that engages in political and legislative lobbying and educational activities regarding the competitive bidding procurement and nutrient credit trading program in Pennsylvania (and elsewhere), shares certain key management members with the Company. During the year ended

June 30, 2017

the Company recorded expenses of

$165,650

for consulting costs incurred on behalf of CABS (the Company contributed

$68,900

to CABS and issued

129,000

shares of its restricted common stock valued at

$96,750

to pay

third

party consultants for services to CABS) and during the year ended

June 30, 2018,

the Company received reimbursements from CABS for the prior year expenses of

$41,000

incurred by the Company in providing support for CABS.

During the

three

and

nine

months ended

March 31, 2019,

the Company received

nil

and

$30,000

for expense reimbursements from CABS, respectively. The Company received

no

expense reimbursements for the

three

and

nine

months ended

March 31, 2018.

The Company also issued

16,000

shares of its restricted common stock valued at

$8,000

for

third

party consulting expenses on behalf of CABS during the

nine

months ended

March 31, 2019

and paid CABS

$12,500

in consulting fees, while there were

no

such expenses for the

nine

months ended

March 31, 2018.

During the

nine

months ended

March 31, 2019,

the Company determined that it had made omissions in

not

disclosing certain related party transactions with CABS during the years ended

June 30, 2018

and

2017.

  The Company determined the omissions are immaterial and prior year financial statements and reports previously filed, would

not

have to be amended.  The Company will disclose comparative prior period disclosures in future filings. 

XML

Note 10 - Subsequent Events

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Subsequent Events [Text Block]

10.

     SUBSEQUENT EVENTS:

The Company has evaluated events that occurred subsequent to

March 31, 2019

for recognition and disclosure in the financial statements and notes to the financial statements.

From

April 1, 2019

through

May 8, 2019,

the Company has issued

2,734

shares of the Company’s common shares to an employee for services valued at approximately

$2,000

and has issued

20,000

shares to a consultant for services valued at approximately

$15,000.

From

April 1, 2019

through

May 8, 2019,

the Company has sold

75,000

Units of its securities at

$0.50

per Unit for aggregate consideration of

$37,500.

Each Unit consists of

one

share of common stock and a callable warrant to purchase ½ share of the Company’s common shares at

$0.75

per share until

December 31, 2020.

XML

Significant Accounting Policies (Policies)

9 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services,

PA1,

and

PA2;

and its

58.9%

owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at

March 31, 2019,

and the results of operations and cash flows of the Company for the

three

and

nine

months ended

March 31, 2019

and

2018.

Operating results for the

three

and

nine

months ended

March 31, 2019

are

not

necessarily indicative of the results that

may

be expected for the year ending

June 30, 2019.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents:

The Company considers all highly liquid investments purchased with an original maturity of

three

months or less to be cash and cash equivalents.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and equipment:

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally

three

to

twenty

years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in

no

related asset being recognized in the Company’s balance sheet) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have

no

direct relationship to the value of the Company’s patents. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset

may

not

be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

Share-based Payment Arrangement [Policy Text Block]

Stock-based compensation:

The Company follows the provisions of Accounting Standards Codification (“ASC”)

718,

which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

Derivatives, Policy [Policy Text Block]

Derivative Financial Instruments:

Pursuant to ASC Topic

815

“Derivatives and Hedging” (“Topic

815”

), the Company reviews all financial instruments for the existence of features which

may

require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

Equity Issuances Warrants Policy [Policy Text Block]

Warrants:

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of credit risk:

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times

may

exceed federally insured limits. The Company has

not

experienced any losses on such accounts.

Minority Interest Policy [Policy Text Block]

Noncontrolling interests:

In accordance with ASC

810,

“Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

Fair Value Measurement, Policy [Policy Text Block]

Fair value measurements:

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has

three

levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

Level

1

– quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level

2

– observable inputs other than Level

1,

quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are

not

active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

Level

3

– assets and liabilities whose significant value drivers are unobservable.

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability

may

fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are

not

practicable to estimate due to the related party nature of the underlying transactions.

Revenue [Policy Text Block]

Revenue Recognition:

The Company currently does

not

generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”)

606

“Revenue from Contracts with Customers”.

Earnings Per Share, Policy [Policy Text Block]

Loss per share:

Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share or increase the earnings per share. During the

three

and

nine

months ended

March 31, 2019

and

2018,

the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

The following table represents the warrants, options and convertible securities excluded from the calculation of basic loss per share:

	March 31, 2019		March 31, 2018
Warrants		16,591,570		12,176,269
Options		7,106,600		6,827,225
Convertible debt		8,449,932		7,337,805
Convertible preferred stock		17,750		16,750

The following is a reconciliation of the denominators of the basic and diluted loss per share computations for the

three

and

nine

months ended

March 31, 2019

and

2018:

	Three months ended March 31, 2019			Three months ended March 31, 2018			Nine months ended March 31, 2019			Nine months ended March 31, 2018
Shares issued – beginning of period		27,121,371			25,011,939			25,939,892			24,748,213
Shares held by subsidiaries (Note 7)		(704,309	)		(704,309	)		(704,309	)		(704,309	)
Shares outstanding – beginning of period		26,417,062			24,307,630			25,235,583			24,043,904
Weighted average shares issued during the period		425,714			158,184			1,055,514			209,903
Diluted weighted average shares – end of period		26,842,776			24,465,814			26,291,097			24,253,807

Use of Estimates, Policy [Policy Text Block]

Use of estimates:

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements:

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change.

In

May 2017,

the FASB issued ASU

No.

2017

-

09

“Scope of Modification Accounting” which clarifies when changes to the terms or conditions of a share-based payment awards must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU

No.

2017

-

09

will be applied prospectively to awards modified on or after the adoption date. The guidance is effective for annual periods, and interim periods within those annual periods beginning after

December 15, 2017,

with early adoption permitted. The adoption of ASU

2017

-

09

did

not

have a material impact on the Company’s financial statements.

XML

Note 2 - Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	March 31, 2019		March 31, 2018
Warrants		16,591,570		12,176,269
Options		7,106,600		6,827,225
Convertible debt		8,449,932		7,337,805
Convertible preferred stock		17,750		16,750

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three months ended March 31, 2019			Three months ended March 31, 2018			Nine months ended March 31, 2019			Nine months ended March 31, 2018
Shares issued – beginning of period		27,121,371			25,011,939			25,939,892			24,748,213
Shares held by subsidiaries (Note 7)		(704,309	)		(704,309	)		(704,309	)		(704,309	)
Shares outstanding – beginning of period		26,417,062			24,307,630			25,235,583			24,043,904
Weighted average shares issued during the period		425,714			158,184			1,055,514			209,903
Diluted weighted average shares – end of period		26,842,776			24,465,814			26,291,097			24,253,807

XML

Note 3 - Property and Equipment (Tables)

9 Months Ended

Mar. 31, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

	March 31, 2019			June 30, 2018
Machinery and equipment	$	2,222,670		$	2,222,670
Buildings and structures		401,470			401,470
Computers and office equipment		173,245			171,613
		2,797,385			2,795,753
Less accumulated depreciation		(2,794,421	)		(2,794,305	)
	$	2,964		$	1,448

XML

Note 7 - Stockholders' Equity (Tables)

9 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Weighted Average, March 31, 2019		Range, March 31, 2019			Weighted Average, March 31, 2018		Range, March 31, 2018
Volatility		69%	58%	-	76%		74%	68%	-	75%
Dividend yield		-		-			-		-
Risk-free interest rate		2.71%	2.52%	-	2.78%		2.44%	1.75%	-	2.64%
Expected term (years)		3.8	1.9	to	4.3		5	3	-	6

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at July 1, 2018		6,827,225		$	1.11		3.8	$	-
Granted		350,000			0.68
Exercised		-			-
Forfeited		-			-
Expired		(70,625	)		1.26
Outstanding at March 31, 2019		7,106,600		$	1.09		3.3	$	57,050
Exercisable at March 31, 2019		7,106,600		$	1.09		3.3	$	57,050

Schedule of Nonvested Share Activity [Table Text Block]

	Options			Weighted Average Grant-Date Fair Value
Nonvested at July 1, 2018		-		$	-
Granted		350,000			0.35
Vested		(350,000	)		0.35
Nonvested at March 31, 2019		-		$	-

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three months ended March 31, 2019		Three months ended March 31, 2018		Nine months ended March 31, 2019		Nine months ended March 31, 2018
General and administrative:
Fair value of stock bonuses expensed	$	-	$	1,500	$	-	$	8,723
Change in fair value from modification of option terms		-		-		211,185		243,761
Change in fair value from modification of warrant terms		-		7,091		118,233		163,956
Fair value of stock options expensed		5,250		682,485		97,375		782,135
Total	$	5,250	$	691,076	$	426,793	$	1,198,575
Research and development:
Fair value of stock bonus expensed	$	-	$	-	$	-	$	15,098
Change in fair value from modification of option terms		-		-		11,115		105,895
Change in fair value from modification of warrant terms		-		219		44,793		132,896
Fair value of stock options expensed		-		587,215		25,875		587,215
Total	$	-	$	587,434	$	81,783	$	841,104

XML

Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Sep. 25, 2014	Jan. 26, 2009
Construction Loan										$ 7,750,000
Impairment of Long-Lived Assets Held-for-use							$ 1,684,562
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total	$ (509,219)	$ (1,730,412)	$ (1,951,116)	$ (2,770,999)	$ (3,018,000)	$ (2,463,000)
Working Capital	10,623,000		10,623,000
Stockholders' Equity Attributable to Parent, Ending Balance	$ (14,289,685)		(14,289,685)		(13,749,276)
Proceeds from Issuance or Sale of Equity, Total			792,000		418,000	$ 452,000
Payments of Stock Issuance Costs			53,437	$ 14,875
Deferred Compensation Liability, Amount Cancelled					2,404,000
Minimum [Member]
Capital Required for Capital Adequacy					2,500,000
Maximum [Member]
Capital Required for Capital Adequacy					$ 50,000,000
PA-1 [Member]
Debt Instrument, Debt Default, Amount									$ 8,137,117
Property, Plant and Equipment of PA1 [Member]
Impairment of Long-Lived Assets Held-for-use			$ 0				$ 1,684,562	$ 3,750,000

XML

Note 2 - Significant Accounting Policies (Details Textual)	6 Months Ended
	Dec. 31, 2018
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	20 years
Centerpoint [Member]
Noncontrolling Interest, Ownership Percentage by Parent	58.90%

XML

Note 2 - Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Warrant [Member]
Antidilutive securities (in shares)	16,591,570	12,176,269
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	7,106,600	6,827,225
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	8,449,932	7,337,805
Convertible Preferred Stock Antidilutive Securities [Member]
Antidilutive securities (in shares)	17,750	16,750

XML

Note 2 - Significant Accounting Policies - Earnings Per Share, Basic and Diluted (Details) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Shares issued – beginning of period (in shares)	27,795,695		27,795,695		27,121,371	25,939,892	25,011,939	24,748,213
Shares held by subsidiaries (Note 7) (in shares)					(704,309)	(704,309)	(704,309)	(704,309)
Shares outstanding – beginning of period (in shares)	27,091,386		27,091,386		26,417,062	25,235,583	24,307,630	24,043,904
Weighted average shares issued during the period (in shares)	425,714	158,184	1,055,514	209,903
Diluted weighted average shares – end of period (in shares)	26,842,776	24,465,814	26,291,097	24,253,807

XML

Note 3 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2018
Impairment of Long-Lived Assets Held-for-use					$ 1,684,562
Depreciation, Total	$ 271	$ 436	$ 966	$ 1,308
Property, Plant and Equipment, Net, Ending Balance	$ 2,964		2,964				$ 1,448
Property, Plant and Equipment of PA1 [Member]
Impairment of Long-Lived Assets Held-for-use			$ 0		1,684,562	$ 3,750,000
Property, Plant and Equipment, Net, Ending Balance					$ 0

XML

Note 3 - Property and Equipment - Property and Equipment (Details) - USD ($)	Mar. 31, 2019	Jun. 30, 2018
Machinery and equipment	$ 2,222,670	$ 2,222,670
Buildings and structures	401,470	401,470
Computers and office equipment	173,245	171,613
Total	2,797,385	2,795,753
Less accumulated depreciation	(2,794,421)	(2,794,305)
Net	$ 2,964	$ 1,448

XML

Note 4 - Deferred Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Deferred Compensation Liability, Current, Total	$ 844,122	$ 345,929	$ 844,122	$ 345,929	$ 421,641
Interest Rate on Deferred Compensation	4.00%		4.00%
Deferred Compensation Conversion Days			5 days
Deferred Compensation Consecutive Trading Days			10 days
Interest Expense, Total	$ 100,282	84,714	$ 290,082	276,815
Interest Expense on Deferred Compensation Obligation [Member]
Interest Expense, Total			14,344	32,299
Interest Expense, Related Party			11,048	26,084
Chief Executive Officer [Member]
Deferred Compensation Liability, Current, Total	447,019	124,612	447,019	124,612
Deferred Compensation, Convertible to Common Stock	$ 300,000		$ 300,000
Deferred Compensation, Convertible to Common Stock, Price Per Share	$ 0.75		$ 0.75
President [Member]
Deferred Compensation Liability, Current, Total	$ 79,016	72,355	$ 79,016	72,355
Deferred Compensation, Convertible to Common Stock, Price Per Share	$ 0.75		$ 0.75
Deferred Compensation, Converted to Units, Amount			$ 87,063
Accounts Payable, Converted to Units, Amount			$ 12,937
Deferred Compensation and Accounts Payable Converted to Units, Shares			200,000
Deferred Compensation and Accounts Payable Converted to Units, Price Per Unit	$ 0.50		$ 0.50
Consultants [Member]
Deferred Compensation Liability, Current, Total	$ 244,603	$ 75,478	$ 244,603	$ 75,478
Interest Rate on Deferred Compensation	3.00%		3.00%
Individual Employee [Member]
Deferred Compensation Liability, Current, Total	$ 984		$ 984
Deferred Compensation Shares Issued upon Conversion			1,348
Former Employee [Member]
Deferred Compensation Liability, Current, Total	$ 72,500		$ 72,500

XML

Note 5 - Loan Payable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		66 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Sep. 25, 2014	Jan. 26, 2009
Construction Loan							$ 7,750,000
PA-1 [Member]
Debt Instrument, Debt Default, Amount						$ 8,137,117
Pennvest Loan [Member]
Construction Loan	$ 9,228,213		$ 9,228,213
Accrued Interest and Late Charges Payable	1,474,213		1,474,213
Line of Credit Facility, Maximum Borrowing Capacity	7,754,000		$ 7,754,000
Term Loan, Period for Interest Only Payments			3 years
Term Loan, Period for Amortization of Principal			10 years
Repayments of Long-term Debt, Total					$ 3,502,000
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year					771,000
Long-term Debt, Maturities, Repayments of Principal in Year Two					794,000
Long-term Debt, Maturities, Repayments of Principal in Year Three					819,000
Long-term Debt, Maturities, Repayments of Principal in Year Four					846,000
Long-term Debt, Maturities, Repayments of Principal in Year Five					873,000
Long-term Debt, Maturities, Repayments of Principal after Year Five					$ 149,000
Interest Expense, Debt, Total	$ 59,109	$ 49,373	$ 172,856	$ 148,121
Pennvest Loan [Member] | Years One Through Five [Member]
Debt Instrument, Interest Rate During Period			2.547%
Pennvest Loan [Member] | Years Six Through Maturity [Member]
Debt Instrument, Interest Rate During Period			3.184%

XML

Note 6 - Convertible Notes Payable - Affiliates (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2016
Interest Expense, Total	$ 100,282	$ 84,714	$ 290,082	$ 276,815
January 2015 Convertible Notes [Member]
Financing Receivable, Interest Rate, Stated Percentage	4.00%		4.00%
Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Financing Receivable, Interest Rate, Stated Percentage	4.00%		4.00%
Warrants Payable With Secured Promissory Notes [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.60		$ 0.60
Class of Warrant or Right, Purchase Price of Warrants or Rights, Per Share	$ 0.10		$ 0.10
Chief Executive Officer [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Financing Receivable, Interest Rate, Stated Percentage	4.00%		4.00%
Interest Receivable	$ 7,956		$ 7,956
Chief Executive Officer [Member] | Warrants Payable With Secured Promissory Notes [Member]
Class of Warrant or Right, Number Agreed to Sell			3,000,000
President [Member]
Number of Shares Per Unit	1		1
Number of Warrants Per Unit	1		1
President [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Interest Receivable	$ 796		$ 796
President [Member] | Warrants Payable With Secured Promissory Notes [Member]
Class of Warrant or Right, Number Agreed to Sell			300,000
January 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Warrants Payable With Secured Promissory Notes [Member]
Secured Promissory Notes Payable with Warrants	300,000		$ 300,000
January 2015 Convertible Notes [Member] | President [Member] | Warrants Payable With Secured Promissory Notes [Member]
Secured Promissory Notes Payable with Warrants	$ 30,000		$ 30,000
January 2015 Convertible Notes [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage						4.00%
Number of Shares Per Unit	1		1
Number of Warrants Per Unit	0.5		0.5
Conversion Price Per Unit	$ 0.50		$ 0.50
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1		$ 1
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 0
Interest Expense, Total	$ 25,677	25,677	78,172	78,172
January 2015 Convertible Notes [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]
Convertible Notes Payable, Noncurrent	1,713,318	1,654,736	1,713,318	1,654,736
January 2015 Convertible Notes [Member] | Convertible Debt [Member] | President [Member]
Convertible Notes Payable, Noncurrent	889,703	859,282	889,703	859,282
January 2015 Convertible Notes [Member] | Convertible Debt [Member] | Executive Vice Chairman [Member]
Convertible Notes Payable, Noncurrent	442,547	427,416	442,547	427,416
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member]
Convertible Notes Payable, Total	158,544		158,544				$ 405,831
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member]
Convertible Notes Payable, Total	18,716	447,989	18,716	447,989			82,921
September 2015 Convertible Notes [Member] | Chief Financial Officer [Member]
Convertible Notes Payable, Total							$ 16,382
September 2015 Convertible Notes [Member] | Shareholder [Member]
Convertible Notes Payable, Total	$ 396,271	91,417	$ 396,271	91,417
September 2015 Convertible Notes [Member] | CEO, President, and Executive Vice Chairman [Member]
Convertible Notes Payable, Total		18,061		18,061
September 2015 Convertible Notes [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage					4.00%
Conversion Price Per Unit	$ 0.60		$ 0.60
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 0
Interest Expense, Total	$ 5,293	$ 5,341	15,712	$ 15,743
Replacement Note Held as Collateral [Member] | Chief Executive Officer [Member]
Convertible Notes Payable, Total	$ 130,000		130,000
Convertible Debt, Amount Sold to a Shareholder By an Officer			$ 300,000

XML

Note 7 - Stockholders' Equity (Details Textual)		3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 01, 2014 $ / shares shares	Mar. 31, 2019 USD ($) $ / shares shares	Mar. 31, 2018 USD ($)	Mar. 31, 2019 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) shares	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) shares	Dec. 31, 2018 shares	Aug. 01, 2018 USD ($) $ / shares shares	Dec. 31, 2017 shares
Common Stock Voting Rights Votes Per Share				1
Shares Held by Subsidiaries						704,309	704,309	704,309		704,309
Stock Issued During Period, Value, Issued for Services | $				$ 45,256
Stock Issued During Period, Shares, CommissionsOnSaleOfUnits				1,028
Shares Issued for Warrant Exercise Commissions | $				$ 514
Proceeds from the Sale of Units | $				792,365	306,997
Adjustments to Additional Paid in Capital, Warrant Issued | $				$ 6,250
Class of Warrant or Right, Outstanding		5,229,188		5,229,188
Weighted Average Exercise Price for Outstanding Warrants | $ / shares		$ 0.95
Weighted Average Remaining Contractual Life for Outstanding Warrants		3 years 292 days
Modification of Warrants | $				$ 163,026
Interest Expense Related to the Modification of Warrants | $				$ 7,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				350,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $				$ 123,250	1,376,250
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $		$ 0		$ 0
Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Financing Receivable, Interest Rate, Stated Percentage		4.00%		4.00%
Expired [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		70,069		70,069
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		30,000,000		30,000,000
Share-based Payment Arrangement, Expense | $		$ 5,250	$ 1,269,700	$ 123,250	$ 1,369,350
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				350,000	2,647,500
Subscription Agreement [Member]
Share Price | $ / shares		$ 0.75		$ 0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50		$ 0.50
Number of Warrants Per Unit		1		1
Warrant Component of Equity Unit, Number of Shares of Restricted Common Stock Called by Each Warrant		0.5		0.5
Sale of Units, Number Of Units Issued				1,584,733
Proceeds from the Sale of Units | $				$ 792,365
Proceeds from Sale of Units, Net of Commissions | $				$ 738,928
Stock Issued During Period, Shares, New Issues				1,584,733
Class of Warrant or Right, Issued During Period				792,369
Warrant Fair Value Price Per Share | $ / shares		$ 0.05		$ 0.05
Adjustments to Additional Paid in Capital, Warrant Issued | $		$ 28,176
Adjustments to Additional Paid in Capital, Other | $		$ 764,189
Subscription Agreement [Member] | Restricted Stock [Member]
Number of Shares Per Unit		1		1
Subscription Agreement Two [Member]
Share Price | $ / shares		$ 0.75		$ 0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50		$ 0.50
Number of Warrants Per Unit		1		1
Warrant Component of Equity Unit, Number of Shares of Restricted Common Stock Called by Each Warrant		0.5		0.5
Sale of Units, Number Of Units Issued		1,584,733
Proceeds from the Sale of Units | $		$ 792,365
Proceeds from Sale of Units, Net of Commissions | $		$ 738,928
Stock Issued During Period, Shares, New Issues		1,584,733
Class of Warrant or Right, Issued During Period		792,369
Warrant Fair Value Price Per Share | $ / shares		$ 0.05		$ 0.05
Adjustments to Additional Paid in Capital, Warrant Issued | $		$ 28,176
Adjustments to Additional Paid in Capital, Other | $		$ 764,189
Subscription Agreement Two [Member] | Restricted Stock [Member]
Number of Shares Per Unit		1		1
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.60		$ 0.60
Class of Warrant or Right, Outstanding		16,600,000		16,600,000
Minimum [Member] | Expired [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.85		$ 0.85
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		2		2
Maximum [Member] | Expired [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 3		$ 3
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Employees and Consultants [Member]
Stock Issued During Period, Value, Issued for Services | $		$ 45,256
Employees and Consultants [Member] | Minimum [Member]
Stock Issued During Period, Shares, Issued for Services				70,042
Share Price | $ / shares		$ 0.50		$ 0.50
Employees and Consultants [Member] | Maximum [Member]
Share Price | $ / shares		$ 0.74		$ 0.74
President [Member]
Number of Shares Per Unit		1		1
Number of Warrants Per Unit		1		1
Deferred Compensation, Converted to Units, Amount | $				$ 87,063
Accounts Payable, Converted to Units, Amount | $				$ 12,937
Deferred Compensation and Accounts Payable Converted to Units, Shares				200,000
Deferred Compensation, Loan Payable, and Accounts Payable Converted to Units, Price Per Unit | $ / shares		$ 0.50		$ 0.50
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.5		0.5
Class of Warrant or Right, Number for Which Expiration Date Extended				3,104,010
Modification of Warrants | $				$ 68,758
President [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Interest Receivable | $		$ 796		796
President [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2023 [Member]
Financing Receivable, after Allowance for Credit Loss, Total | $		$ 30,000		$ 30,000
Financing Receivable, Interest Rate, Stated Percentage		4.00%		4.00%
Interest Receivable | $		$ 796		$ 796
President [Member] | Warrants Related to the Conversion of Deferred Compensation and Accounts Payable into Units [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.75		$ 0.75
President [Member] | Warrants Expiring on December 31, 2023 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.60		$ 0.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		300,000		300,000
Execution Bonus as Percentage of Exercised Options and Warrants		75.00%		75.00%
President [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Plan Modification, Incremental Cost | $				$ 222,300
Chief Executive Officer [Member]
Class of Warrant or Right, Number for Which Expiration Date Extended				1,765,000
Modification of Warrants | $				$ 88,250
Chief Executive Officer [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Financing Receivable, after Allowance for Credit Loss, Total | $		$ 300,000		$ 300,000					$ 300,000
Financing Receivable, Interest Rate, Stated Percentage		4.00%		4.00%
Interest Receivable | $		$ 7,956		$ 7,956
Chief Executive Officer [Member] | Warrants Expiring on December 31, 2025 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.60		$ 0.60					$ 0.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,000,000		3,000,000					3,000,000
Consultant [Member]
Class of Warrant or Right, Issued During Period				125,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		125,000		125,000
Class of Warrant or Right, Issued During the Period, Value Issued for Expenses | $				$ 6,250
Consultant [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.74		$ 0.74
Consultant [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1.20		$ 1.20
Centerpoint [Member]
Shares Held by Subsidiaries		704,309		704,309
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	200	200		200		200
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.01	$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Convertible Option Per Share | $ / shares	$ 2
Preferred Stock, Dividend Rate, Percentage	2.50%
Preferred Stock, Redemption Price Per Share | $ / shares	$ 100
Convertible Preferred Stock Redemption Period	3 years
Dividends, Preferred Stock, Total | $				$ 1,500		$ 2,000	$ 2,000
Dividends Payable | $		$ 15,500		$ 15,500

XML

Note 7 - Stockholders' Equity - Black-scholes Valuation Assumptions for Options (Details) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Volatility
Dividend yield
Risk-free interest rate
Expected term (Year)
Weighted Average [Member]
Volatility	69.00%	74.00%
Risk-free interest rate	2.71%	2.44%
Expected term (Year)	3 years 292 days	5 years
Minimum [Member]
Volatility	58.00%	68.00%
Risk-free interest rate	2.52%	1.75%
Expected term (Year)	1 year 328 days	3 years
Maximum [Member]
Volatility	76.00%	75.00%
Risk-free interest rate	2.78%	2.64%
Expected term (Year)	4 years 109 days	6 years

XML

Note 7 - Stockholders' Equity - Stock Options Activity (Details) - USD ($)	9 Months Ended	21 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Jun. 30, 2018
Outstanding (in shares)	6,827,225
Outstanding, weighted-average exercise price (in dollars per share)	$ 1.11
Outstanding, weighted-average remaining contractual life (Year)	3 years 109 days	3 years 292 days
Outstanding, aggregate intrinsic value	$ 57,050	$ 57,050
Granted, options (in shares)	350,000
Granted, weighted-average exercise price (in dollars per share)	$ 0.68
Exercised, options (in shares)
Exercised, weighted-average exercise price (in dollars per share)
Forfeited, options (in shares)
Forfeited, weighted-average exercise price (in dollars per share)
Expired, options (in shares)	(70,625)
Expired, weighted-average exercise price (in dollars per share)	$ 1.26
Outstanding (in shares)	7,106,600	7,106,600
Outstanding, weighted-average exercise price (in dollars per share)	$ 1.09	$ 1.09
Exercisable, options (in shares)	7,106,600	7,106,600
Exercisable, weighted-average exercise price (in dollars per share)	$ 1.09	$ 1.09
Exercisable, weighted-average remaining contractual life (Year)	3 years 109 days
Exercisable, aggregate intrinsic value	$ 57,050	$ 57,050

XML

Note 7 - Stockholders' Equity - Nonvested Share Activity (Details)	9 Months Ended
	Mar. 31, 2019 $ / shares shares
Nonvested (in shares) | shares
Nonvested, weighted-average grant-date fair value (in dollars per share) | $ / shares
Granted, options (in shares) | shares	350,000
Granted, weighted-average grant-date fair value (in dollars per share) | $ / shares	$ 0.35
Vested (in shares) | shares	(350,000)
Vested, weighted-average grant-date fair value (in dollars per share) | $ / shares	$ 0.35
Nonvested (in shares) | shares
Nonvested, weighted-average grant-date fair value (in dollars per share) | $ / shares

XML

Note 7 - Stockholders' Equity - Allocation of Recognized Period Costs (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Option [Member]
Allocated Share-based Compensation Expense	$ 5,250	$ 1,269,700	$ 123,250	$ 1,369,350
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	5,250	691,076	426,793	1,198,575
Change in fair value from modification of warrant terms		7,091	118,233	163,956
General and Administrative Expense [Member] | Stock Bonus [Member]
Allocated Share-based Compensation Expense		1,500		8,723
General and Administrative Expense [Member] | Share-based Payment Arrangement, Option [Member]
Allocated Share-based Compensation Expense	5,250	682,485	97,375	782,135
Change in fair value from modification of option terms			211,185	243,761
Research and Development Expense [Member]
Allocated Share-based Compensation Expense		587,434	81,783	841,104
Change in fair value from modification of warrant terms		219	44,793	132,896
Research and Development Expense [Member] | Stock Bonus [Member]
Allocated Share-based Compensation Expense				15,098
Research and Development Expense [Member] | Share-based Payment Arrangement, Option [Member]
Allocated Share-based Compensation Expense		587,215	25,875	587,215
Change in fair value from modification of option terms			$ 11,115	$ 105,895

XML

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)				1 Months Ended	9 Months Ended
	Oct. 10, 2016	Sep. 25, 2014	May 15, 2013	Feb. 28, 2018	Mar. 31, 2019	Aug. 01, 2018	Jun. 30, 2018	Jun. 30, 2017	Apr. 27, 2017	Oct. 31, 2016	Jun. 30, 2014
Extension of Exercise Period Annual Payment per Option or Warrant			$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance					7,106,600		6,827,225
Class of Warrant or Right, Outstanding					5,229,188
Pennvest Loan [Member]
Loss Contingency, Damages Sought, Value		$ 8,137,117
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.60
Class of Warrant or Right, Outstanding					16,600,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2
Exercise Bonus [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance					6,934,600
Class of Warrant or Right, Outstanding					12,032,095
Exercise Bonus [Member] | Minimum [Member]
Execution Bonus as Percentage of Exercised Options and Warrants					50.00%
Exercise Bonus [Member] | Maximum [Member]
Execution Bonus as Percentage of Exercised Options and Warrants					90.00%
President [Member]
Monthly Officers' Cash Compensation	$ 18,000
President [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Interest Receivable					$ 796
President [Member] | FY2016 Extension Agreement [Member] | Extension Bonus [Member]
Deferred Compensation, Maximum Convertible Amount	$ 125,000								$ 300,000	$ 125,000
Deferred Compensation, Stock Conversion, Price Per Share	$ 0.75								$ 0.75	$ 0.75
President [Member] | February 2018 Extension Agreement [Member] | Extension Bonus [Member]
Annual Salary				$ 372,000
Monthly Compensation, Life Insurance				$ 2,000
Chief Executive Officer [Member]
Monthly Officers' Cash Compensation					$ 31,000
Chief Executive Officer [Member] | Warrants Expiring on December 31, 2025 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					3,000,000	3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.60	$ 0.60
Chief Executive Officer [Member] | Secured Promissory Note, Consideration for Warrants Expiring on December 31, 2025 [Member]
Financing Receivable, after Allowance for Credit Loss, Total					$ 300,000	$ 300,000
Note Receivable, Collateral						$ 300,000
Interest Receivable					$ 7,956
Chief Executive Officer [Member] | Stock Bonus [Member]
Execution Bonus as Percentage of Exercised Options and Warrants			50.00%
Chief Executive Officer [Member] | FY2016 Extension Agreement [Member] | Extension Bonus [Member]
Deferred Compensation, Maximum Convertible Amount									$ 300,000
Deferred Compensation, Stock Conversion, Price Per Share									$ 0.75
CEO and President [Member] | Exercise Bonus [Member]
ContingentStockBonusPercentageThresholdForIssuance			50.00%
Extension of Exercise Period			5 years
Extension of Exercise Period Annual Payment per Option or Warrant			$ 0.01
Executive Vice Chairman and Other Board Member [Member] | Exercise Bonus [Member]
Execution Bonus as Percentage of Exercised Options and Warrants											50.00%
Two Former Employees [Member] | Exercise Bonus [Member]
Execution Bonus as Percentage of Exercised Options and Warrants							50.00%
CEO, President, and Executive Vice Chairman [Member]
Execution Bonus, Annual Payment Per Option or Warrant					$ 0.01
CEO, President, and Executive Vice Chairman [Member] | Exercise Bonus [Member]
Execution Bonus as Percentage of Exercised Options and Warrants							75.00%	50.00%

XML

Note 9 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017
Stock Issued During Period, Value, Issued for Services			$ 45,256
Coalition for Affordable Bay Solutions [Member]
Related Party Transaction, Expenses from Transactions with Related Party						$ 165,650
Related Party Transaction, Contributions						$ 68,900
Stock Issued During Period, Shares, Issued for Services			16,000			129,000
Stock Issued During Period, Value, Issued for Services			$ 8,000			$ 96,750
Related Party Transaction, Reimbursements	$ 0	$ 0	30,000	$ 0	$ 41,000
Coalition for Affordable Bay Solutions [Member] | Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction			$ 12,500	$ 0

XML

Note 10 - Subsequent Events (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	May 08, 2019	Mar. 31, 2019
Stock Issued During Period, Value, Issued for Services		$ 45,256
Sale of Units, Value		$ 792,365
Subsequent Event [Member]
Sale of Units, Number Of Units Issued	75,000
Shares Issued, Price Per Share	$ 0.50
Sale of Units, Value	$ 37,500
Number of Shares Per Unit	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.5
Subsequent Event [Member] | An Employee [Member]
Stock Issued During Period, Shares, Issued for Services	2,734
Stock Issued During Period, Value, Issued for Services	$ 2,000
Subsequent Event [Member] | Consultant [Member]
Stock Issued During Period, Shares, Issued for Services	20,000
Stock Issued During Period, Value, Issued for Services	$ 15,000